











































The	 immune	 system	 is	 an	 organism’s	 defence	 to	 protect	 the	 body	 against	 invading	
pathogens.	 T	 cells	 are	 one	 of	 the	 major	 components	 and	 essential	 for	 immune	
responses.	 The	 early	 growth	 response	 gene	 (Egr2)	 in	 T	 cells	 is	 important	 for	
maintaining	 immune	 functions	 of	 T	 cells	 by	 promoting	 adaptive	 immune	 responses,	
while	 controlling	 inflammation	 and	 preventing	 the	 development	 of	 autoimmune	
diseases.	 A	 recent	 study	 by	 our	 group	 demonstrated	 the	 function	 of	 Egr2	 as	 a	




In	 this	 study,	 Egr2	 was	 found	 to	 be	 significantly	 induced	 in	 tumour	 infiltrating	
lymphocytes	 (TILs)	 in	 a	 mouse	 melanoma	 tumour	 model.	 Deficiency	 of	 Egr2	 and	 3	
resulted	 in	 rapid	 growth	 of	 tumour	 with	 impaired	 TIL	 expansion.	 The	 reduced	
expansion	 of	 TILs	 in	 Egr2/3	 deficient	 mice	 were	 impaired	 in	 IL-2	 production	 and	
expressed	low	levels	of	proliferation	marker	Ki-67,	suggesting	the	positive	role	of	Egr2	
in	 CD8+	 TIL	 expansion	 and	 tumour	 regression.	 Furthermore,	 Egr2	 expression	 was	





First	 and	 foremost,	 I	must	 thank	 the	Almighty	God,	 the	merciful	 and	 the	gracious,	 for	
giving	me	the	ability,	strength	and	opportunity	to	study	and	undertake	this	research.	He	





Special	 thanks	 go	 to	 Dr	 A	 L	 J	 Symonds	 and	 Dr	 T	 Miao	 for	 their	 assistance	 in	 the	
experiments	and	explaining	techniques.	I	would	also	like	to	thank	Dr	Becky	Omodho	for	
her	kind	help	and	expertise	wherever	required.	
I	 have	 great	 pleasure	 in	 acknowledging	 my	 appreciation	 to	 my	 colleagues	 and	 close	
friends	at	 the	office,	Dr	Hussein	Al-Ali,	 Joshua,	Hajar,	Saba,	Marianne	and	Daniel,	with	
whom	I	shared	very	memorable	moments	and	propelled	me	on	the	course	of	my	life	and	
this	 thesis.	 Thank	 you	 for	 all	 the	 motivation,	 insightful	 guidance,	 the	 laughs	 in	 the	
middle	of	the	day	and	creating	a	friendly	and	warm	atmosphere.	
Four	very	 important	people	 formed	a	pillar	of	 support	and	dedication	network	 in	my	
life	and	words	are	limited	to	describe	their	sacrifices	that	they	constantly	made	to	keep	
my	dreams	 alive	 and	went	 out	 of	 their	way	 to	 see	me	 achieve	my	goals,	 they	 are	my	
parents	and	my	uncles.	To	my	mum,	Nasrin	Faraji,	my	father	Karim	Taefehshokr,	and	to	




gratitude	 to	 my	 brother	 Sina	 for	 all	 his	 unwavering	 love,	 efficient	 guidance	 and	





























































































































































































































































































































has	 many	 facets	 and	 generally	 can	 be	 divided	 into	 adaptive	 immunity	 (acquired	






of	 exogenous	 and	 endogenous	 danger	 signals	 and	 can	 be	 divided	 into	 cellular	 and	
humoral	components.	Cellular	innate	immunity	is	largely	dependent	upon	myeloid	cells	
including	 mononuclear	 and	 polymorphonuclear	 phagocytes	 (Beutler,	 2004).	
Mononuclear	phagocytes	are	macrophages	derived	from	monocytes	in	the	blood,	which	
are	effective	antigen	presenting	cells	to	T	cells	of	adaptive	immunity.	They	are	capable	
of	 engulfing	 and	 killing	 microbes,	 while	 polymorphonuclear	 phagocytes,	 including	
neutrophils,	basophils	and	eosinophils,	 are	 indispensable	 in	 containment	of	 infections	
(Beutler	and	Rietschel,	2003).	Also,	natural	killer	 (NK)	 cells	 are	 important	 features	of	
cellular	innate	immunity,	which	have	a	host-protective	role	against	viral	infections	and	
tumours	via	release	of	perforin	and	granzymes	(Tosi,	2005).	The	humoral	component	of	




mucosal	 surfaces	 from	 infection	 and	 obstruct	 acute	 invasive	 infections.	 They	 include	
two	large	families	of	defensins	and	cathelicidins	(Ganz,	2004,	Singh	et	al.,	2002).	
Innate	 immune	 receptors,	 pattern	 recognition	 receptors	 (PRR),	 recognise	 microbial	
infection	 through	 pathogen	 associated	molecular	 patterns	 (PAMP),	 and	 among	 these,	
Toll-like	 receptors	 expressed	 on	 many	 epithelial	 cells,	 mononuclear	 phagocytes	 and	
leucocytes	have	a	crucial	role	in	recognition	of	microbes.	They	can	induce	activation	of	
inflammation	 and	 antimicrobial	 immune	 responses	 (Medzhitov,	 2001),	 for	 example,	
TLR2	 and	 TLR4	 binds	 mainly	 to	 gram-positive	 cell	 components	 and	 gram-negative	
lipopolysaccharide	respectively	(Tosi,	2005).		
1.2.1	Complement	system	
The	 complement	 system	 consists	 of	 about	 30	 plasma	 proteins	 that	 are	 present	 as	
membrane-associated	proteins	or	soluble	proteins	in	the	blood	and	its	main	function	is	
recognition	 and	 elimination	 of	 microbes	 (Sarma	 and	 Ward,	 2011).	 In	 addition,	
complement	facilitates	the	clearance	of	apoptotic	cells	and	cellular	debris,	with	defects	
in	 its	regulators	causing	autoimmune	diseases	(Zipfel	and	Skerka,	2009).	Complement	
activation	 can	 be	 achieved	 through	 three	 different	 pathways	 including	 the	 classical,	
alternative	 and	 lectin	 pathways	 (Cho,	 2015).	 The	 classical	 pathway	 is	 triggered	 by	
formation	 of	 immune	 complexes	 (target	 bound	 antibody),	 the	 lectin	 pathway	 by	 the	
recognition	of	microbial	polysaccharide	structures	by	binding	of	mannan-binding	lectin	
(MBL)	 to	 mannose	 residues	 on	 microbial	 surfaces	 and	 the	 alternative	 pathway	 is	
initiated	 by	 carbohydrates,	 lipids	 and	 proteins	 found	 on	 foreign	 surfaces	 (Sarma	 and	
Ward,	2011,	Cho,	2015).	Finally,	the	terminal	step	leads	to	the	formation	of	membrane	
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attack	 complex	 (MAC),	 which	 creates	 a	 pore	 in	 the	 membrane,	 leading	 to	 cell	 lysis	
(Zipfel	and	Skerka,	2009).	
1.2.2	Phagocytosis	
Is	 one	 of	 the	 initial	 steps	 in	 triggering	 host	 defence,	 inflammation	 and	 dying	 cell	
clearance,	which	is	mediated	by	phagocytes	including	macrophages,	dendritic	cells	and	
granulocytes	 (Murphy,	2012).	Phagocytes	are	alerted	via	different	 chemotactic	 agents	
released	by	invaders	and	phagocytes	through	PRR	binding	to	their	targets	(PAMPs)	in	a	
process	known	as	particle	recognition	(Aderem,	2013).	Phagocytes	extend	their	plasma	
membrane	 to	 engulf	 and	 internalise	 pathogens	 in	 phagosomes.	 By	 fusing	 lysosomes,	
they	 mature	 into	 a	 phagolysosome	 where	 pathogens	 are	 killed	 and	 degraded	 by	
different	 microbicidal	 mechanisms	 (Owen	 et	 al.,	 2013),	 including	 antimicrobial	
peptides,	 low	 pH,	 hydrolytic	 enzymes	 as	 well	 as	 reactive	 oxygen	 and	 nitrogen	
intermediates	 (Aderem,	 2013).	 Efficiency	 of	 phagocytosis	 is	 increased	 by	 tagging	 of	
invading	microbes	 via	 opsonins	 in	 a	 process	 known	 as	 opsonisation	 (Greenberg	 and	
Grinstein,	2002).		
1.2.3	Inflammation	
Inflammation	 is	 pervasive	 form	 of	 defence	 initiated	 due	 to	 the	 disrupted	 tissue	
homeostasis	 and	 different	 stimulants,	 including	 allergens,	 virulence	 factors,	 foreign	
bodies	and	necrotic	cells,	which	leads	to	inflammatory	responses	(Ashley	et	al.,	2012).	
Protective	 inflammatory	 responses	 involve the recruitment of leukocytes	 and	 plasma	
proteins	into	the	perturbed	tissue	and	local	sites	of	infection	(Ashley	et	al.,	2012,	Turvey	
and	Broide,	2010).	The	main	functions	of	inflammation	is	defined	as	the	quick	isolation	




by	 innate	 immune	 PRR	 receptors	 e.g.	 transmembrane	 Toll-like	 receptors	 (TLR)	 and	
intracellular	nucleotide-binding	oligomerisation-domain	proteins	(NOD)-like	receptors	
(NLR)	on	tissue-resident	macrophages	(Turvey	and	Broide,	2010,	Murphy,	2012,	Tosi,	
2005,	Medzhitov,	 2001).	 Then,	 this	 triggers	mediators	 of	 inflammation:	 the	 cytokines	
(interleukins,	interferons,	and	chemokines),	eicosanoids	and	vasoactive	amines	(Turvey	
and	Broide,	2010,	Medzhitov,	2008).	Inflammation	alongside	the	cytokine	milieu	assists	
the	 maturation	 and	 activation	 of	 dendritic	 cells	 that	 provide	 the	 bridge	 between	
pathogen	 infection	 and	 autoimmunity	 (Ray	 et	 al.,	 2013).	 In	 this	 mechanism,	 T	
lymphocytes	that	escape	tolerance	against	the	self-antigens	in	the	thymus	are	activated	
when	 self-peptides	 are	 altered	 due	 to	 an	 external	 stimulus,	 leading	 to	 cellular	
infiltration	and	local	inflammation	(Turley,	2002).	In	recent	years,	it	has	been	reported	





• calor	 (heat)	 results	 from	 increased	 blood	 flow	 and	 the	 metabolic	 activities	 of	
cytokines	in	peripheral	parts	of	the	body	
• dolor	 (pain)	 associated	 with	 distortion	 of	 tissues	 caused	 by	 oedema	 and	
mediators	of	inflammation,	such	as	prostaglandins	and	serotonin	




Inflammation	may	 be	 acute,	 lasting	 for	 a	 few	 days	 that	 can	 lead	 to	 the	 resolution	 of	
inflammation	 or	 chronic	 with	 longer	 duration	 of	 response	 and	 constant	 presence	 of	
inflammatory	cells	and	molecules	(Kumar	et	al.,	2007).	
1.2.3.1	Acute	Inflammation	
This	 is	a	protective	 linear	progression	of	response	mounted	by	the	 immune	system	in	
response	 to	 stimulus	 to	 eliminate	harmful	 pathogens	 and	 toxic	 substances	 (Ryan	 and	
Majno,	1977,	Delgado	et	al.,	2003).	The	initiation	step	of	the	acute	phase	inflammatory	
response	is	marked	by	the	dilation	of	blood	vessels,	vasodilation,	to	allow	the	exudation	
of	 polymorphonuclear	 neutrophils,	 plasma	 proteins	 and	 clotting	 factors	 into	
extravascular	 tissues	 spaces	 to	 prevent	 the	 spread	 of	 infectious	 agents	 (Figure	 1.1)	
(Ashley	 et	 al.,	 2012,	 Medzhitov,	 2008).	 Activated	 neutrophils	 create	 a	 cytotoxic	
environment,	removing	their	targets	indiscriminately	by	the	release	of	toxic	substances	
from	 their	 granules.	 These	 noxious	 chemicals	 include	 reactive	 oxygen	 species	 (ROS),	
reactive	 nitrogen	 species,	 cathepsin	 G,	 proteinase	 3	 and	 elastase	 (Medzhitov,	 2008).	
After	 pathogen	 elimination,	 pro-resolution	 molecules	 including	 lipoxin,	 an	 anti-
inflammatory	agent,	 reduce	vascular	permeability,	 promoting	 the	 recruitment	of	non-
phlogistic	monocytes	respectively,	which	are	required	 for	wound	healing	 (Serhan	and	
Savill,	 2005).	 These	 monocytes	 differentiate	 into	 phagocytic	 macrophages	 upon	
activation	 to	 clear	 apoptotic	 neutrophils	 and	 dying	 cells,	 leading	 to	 promotion	 of	
resolution	and	repair	of	damaged	tissues	(Figure	1.1)	(Savill,	2001,	Godson	et	al.,	2000).	
Also,	other	 lipid	mediators	and	anti-inflammatory	cytokines,	 like	 resolvins	 (generated	
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from	 omega-3	 unsaturated	 fatty	 acid),	 protectins	 and	 transforming	 growth	 factor-β	
(TGF-β),	play	an	important	role	in	the	resolution	of	inflammation,	in	which	they	retard	
further	 neutrophil	 infiltration	 by	 initiating	 apoptosis	 and	 suppressing	 protein	
inflammatory	signalling	from	TLR	(Serhan	and	Savill,	2005,	Medzhitov,	2008).	
1.2.3.2	Chronic	Inflammation	
The	 regulation	 and	 control	 of	 inflammatory	 responses	 is	 important	 in	 maintaining	
homeostasis	 and	 avoiding	 pathological	 conditions,	 so	 pro-inflammatory	 and	 anti-
inflammatory	mediators	should	be	tightly	regulated	and	balanced	(Hotamisligil,	2006).	
Repeated	episodes	of	acute	 inflammation	can	also	 lead	to	chronic	 inflammation,	while	
infectious	 organisms	 that	 are	 resistant	 to	 host	 defence	 and	 persist	 in	 tissues	 for	
extended	periods	can	also	cause	chronic	 inflammation	(Delgado	et	al.,	2003,	Ashley	et	
al.,	 2012).	 Infiltration	 of	 circulating	 mononuclear	 macrophages,	 lymphocytes	 and	
plasma	cells	to	the	tissue	sites	is	the	hallmark	of	chronic	inflammation	often	associated	
with	tissue	destruction,	autoimmunity	(Medzhitov,	2008).	Due	to	the	prolonged	nature	
of	 the	 chronic	 inflammatory	 response,	 the	 host	 attempts	 to	 change	 from	 a	 tissue-
damaging	mode	 to	 a	mode	 that	promotes	 tissue	 repair	by	 replacing	 them	with	 either	
cells	of	the	same	type	or	fibrous	connective	tissues	(Figure	1.1).	Sometimes,	the	host	is	
not	 capable	 of	 repairing	 the	 damaged	 tissue,	 thus	 leading	 to	 fatality	 (Nathan,	 2002).	
Chronic	inflammation	has	also	given	rise	to	the	development	of	cancers,	cardiovascular	
and	neurodegenerative	diseases,	other	severe	systemic	 inflammatory	diseases,	as	well	






Figure	 1.1	 Schematic	 representing	 acute	 and	 chronic	 inflammation.	 In	 acute	 inflammation,	
inflammatory	 signals	 ends	days	 later	 and	neutrophils	 are	 recruited	 to	 the	 site	 of	 injury	 to	 resolve	
inflammation.	On	the	other	hand,	chronic	inflammation	may	last	weeks	and	results	in	the	infiltration	


















immune	 cell	 development,	 immune-regulation,	 and	 modulation	 of	 immune	 effector	
functions.	They	play	a	crucial	role	 in	maintaining	 lymphocyte	homeostasis	under	both	




2,	 is	 historically	 recognised	 as	 a	 promoter	 factor	 that	 can	 enhance	 cell	 proliferation,	
whereas	 other	 cytokines,	 such	 as	 IL-10	 and	 TNF-β	 primarily	 produced	 by	 Treg	 cells,	





As	 mentioned	 earlier,	 IL-2	 contributes	 a	 pivotal	 role	 in	 promoting	 lymphoid	
proliferation,	but	a	 far	more	complex	picture	has	been	demonstrated	 in	 IL-2	and	 IL-2	
receptor	 (IL-2R)	 knockout	 mouse	 models.	 Immune	 cells,	 including	 NK	 cells,	 natural	
killer	 T	 cells	 (NKT)	 and	 CD8	 T	 cells	 produce	 IL-2	 and	 CD4	 T	 helper	 cells	 under	
homeostatic	 conditions	mainly	 produce	 IL-2	 in	 secondary	 lymphoid	 organs	 (Boyman	
and	 Sprent,	 2012).	 During	 an	 immune	 response,	 the	 expression	 of	 IL-2	 is	 induced	 in	
large	 amounts	 by	 activated	 antigen-specific	 CD4+	 and	 CD8+	 T	 cells,	 although	 IL-2	
synthesis	by	CD8	cells	is	weak	and	to	a	lesser	extent	than	CD4	cells	(Malek,	2008).	CD25,	
an	 IL-2	 receptor	 subunit,	 is	 the	 third	chain	of	 the	 trimeric	 IL-2R	and	although	 it	does	
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appear	to	contribute	directly	to	signal	transduction,	it	increases	receptor	affinity	for	IL-
2.	Under	antigen-specific	CD4+	and	CD8+	T	 cell	 immune	 response,	 IL-2	 is	produced	 in	
large	 amounts,	 then	 consumed	 by	 CD25	 effector	 T	 cells	 and	 Treg	 cells	 (Boyman	 and	
Sprent,	2012).		
IL-2	 plays	 a	 crucial	 role	 in	 the	 differentiation	 and	 survival	 of	 CD4	 T	 helper	 subsets,	
including	 Th1,	 Th2	 and	 Th17	 along	 with	 homeostasis	 of	 regulatory	 T	 (Treg)	 cells	
(Sharma,	2007),	(Figure	1.2).	IL-2	promotes	Th1	and	Th2	differentiation	mainly	through	
the	induction	of	T-bet	and	IL-4	expression	respectively	(Liao	et	al.,	2011,	Cote-Sierra	et	
al.,	 2004).	 IL-2	 signalling	 also	 downregulates	 IL-6-mediated	 STAT3	 activation	 and	
favours	the	cells	towards	the	development	of	RORγt+	Th17	cells	(Liao	et	al.,	2011).	Due	
to	 diverse	 role	 of	 IL-2	 under	 homeostatic	 and	 infection	 conditions	 in	 the	 immune	
system,	it	is	regulated	through	different	mechanisms. 
One	 of	 the	 mechanisms	 involves	 IL-2	 gene	 silencing	 by	 the	 transcription	 factor	 B	
lymphocyte-induced	 maturation	 protein	 1	 (Blimp1).	 In	 THE	 T	 cell-specific	 Blimp1	
knockout	mouse	model,	mice	developed	aberrant	T	cell	homeostasis	and	fatal	colitis.	It	
was	found	that	Blimp1	is	crucial	 for	directly	repressing	IL-2	transcription,	upon	T	cell	




responses.	 IL-2	 signalling	 affects	 different	 stages	 including	 primary	 expansion,	
contraction,	memory	 generation	 and	 secondary	 expansion.	 The	 primary	 expansion	 of	
CD8	T	 cells	 in	 IL-2	deficient	mice	 is	 threefold	 lower	 compared	 to	WT	counterparts	 in	
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response	 to	 viral	 infection,	 resulting	 in	 less-efficient	 viral	 clearance	 by	 virus-specific	






(2010)	 demonstrated	 that	 a	 subset	 of	 virus-specific	 T	 cells	 sustain	 CD25	 expression	
longer	than	the	rest	during	an	acute	viral	infection.	In	vivo	examinations	revealed	that	
CD25lo	cells,	which	are	less	sensitive	to	IL-2	upregulated	CD127	and	CD62L	to	give	rise	
to	 functional	 long-lived	 memory	 cells,	 while	 CD25hi	 cells	 perceiving	 prolonged	 IL-2	




by	 Tregs	 (Setoguchi	 et	 al.,	 2005).	 IL2-deficient	 mice	 models	 represented	 severe	
autoimmune	 diseases	 such	 as	 type	 1	 diabetes	 and	 EAE,	 in	 which	 symptoms	 were	
prevented	 by	 IL-2	 administration,	 leading	 to	 drastically	 prolonged	 survival	 and	
decreased	 autoantibodies	 (Gutierrez-Ramos	 et	 al.,	 1990,	 Encinas	 et	 al.,	 1999).	 The	
severe	autoimmunity	developed	in	IL-2RBeta-deficient	mice	and	expression	of	IL-2Beta	
chains	in	these	mice	resulted	in	the	production	of	a	normal	proportion	of	natural	Treg	
cells	 that	 inhibited	 the	 development	 of	 severe	 autoimmunity	 (Yu	 et	 al.,	 2009).	 This	
highlights	 the	 use	 of	 IL-2	 for	 strengthening	 natural	 self-tolerance	 and	 inhibiting	
autoimmune	diseases.	 IL-2	 is	 required	 for	 the	 promotion	 of	 Treg	 development	 and	 it	
	 29	
implements	 this	 function	 by	 upregulation	 of	 Foxp3,	 a	 master	 regulator	 of	 the	 Treg	
lineage,	and	CD25	(Burchill	et	al.,	2008,	Burchill	et	al.,	2007).	IL-2	signalling	was	found	






Th	 subsets	 cells	 and	 the	 nature	 of	 the	 antigen	 drives	 the	 differentiation	 pathway,	 leading	 to	 an	
effector	 response.	 In	 this	process,	 IL-2	 signalling	 is	 activated	via	 signal	 transducer	and	activator	of	







Transforming	 growth	 factor	 beta	 (TGF-β)	 is	 pleiotropic	 cytokine	 with	 potent	
inflammatory	 and	 regulatory	 functions	 in	 various	 cells	 of	 the	 immune	 system	 (Li	 and	
Flavell,	2008a).	TGF-β	signalling	in	the	thymus	is	vital	in	the	development	of	NKT,	nTreg	
and	CD8+	T	cells,	when	left	unchecked	cause	rapidly	fatal	autoimmune	diseases	(Marie	
et	al.,	 2006).	The	abolition	of	TGF-β	 leads	 to	 severe	multi-organ	autoimmunity,	 tissue	
necrosis,	 organ	 failure	 and	 death	 (Li	 et	 al.,	 2006,	 Shull	 et	 al.,	 1992).	 TGF-β	 is	
indispensable	 in	 the	 survival	 of	 naïve	 T	 cells	 and	 its	 primary	 function	 is	 the	
maintenance	of	peripheral	 tolerance	by	 inhibiting	the	proliferation	and	differentiation	
of	 CD4	 and	 CD8+	T	 cells	 (Li	 and	 Flavell,	 2008b,	 Li	 et	 al.,	2006).	 Also,	 TGF-β	with	 the	
requirement	of	 IL-2	 is	essential	 for	 the	 induction	of	Foxp3+	T	regulatory	cells	 (iTregs)	
that	can	inhibit	the	induction	of	autoimmunity	(Davidson	et	al.,	2007).	In	contrast,	TGF-




IL-10	 is	another	key	cytokine	with	 immunological	 tolerance	and	suppressive	 function,	
mostly	 expressed	by	 immune	 cells	 including	dendritic	 cells,	macrophages,	NK	 cells,	 B	
cells,	 Th2,	 Th3	 and	 Treg	 cells	 (Moore	 et	 al.,	 2001).	 IL-27	 and	 IL-6	 independently	
promote	the	production	of	IL-10	producing	T	cells	and	TGF-β	in	conjunction	with	IL-27	
or	IL-6	can	enhance	this	condition	(Awasthi	et	al.,	2007,	Stumhofer	et	al.,	2007).	IL-10-
expressing	 intestinal	 T	 cells	 are	 induced	 during	 systemic	 tolerance	 induction,	
highlighting	 the	 intestine	 as	 major	 site	 in	 the	 induction	 of	 immunological	 tolerance	
(Kamanaka	 et	 al.,	 2006).	 IL-10	 plays	 a	 pivotal	 role	 in	 survival	 and	 persistence	 of	
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intracellular	 pathogens,	 such	 as	Leishmania	donovani	and	Mycobacterium	tuberculosis,	
suggesting	 a	 direct	 role	 of	 IL-10	 in	 suppressing	 cell-mediated	 immune	 response	 and	
















































































































as	 transcription	 factors,	 which	 are	 vital	 in	 mediating	 virtually	 all	 cytokine	 driven	
signalling.	They	 can	 also	be	 activated	 in	 response	 to	 growth	 factors,	 such	 as	EGF	and	
PDGF,	through	the	intrinsic	tyrosine	kinases	of	the	cognate	receptors	whose	biological	




obvious	 domains	 of	 the	 protein.	 Beginning	 around	 residue	 130,	 coiled-coil	 domain,	
there	are	four-stranded	long	helical	coils	in	which	interaction	with	other	proteins	occur,	
with	 the	 DNA	 binding	 domain	 comprising	 ~300-500	 residues	 containing	 several	 β-
sheets,	 linker	 domain	 ~500-575	 that	 are	 all	 alpha-helical,	 SH2	 domain	 extending	
















molecule	 binds	 and	 brings	 two	 receptor	 molecules	 together	 to	 form	 a	 dimer.	 This	
dimerisation	brings	the	two	JAKs	in	close	proximity,	where	they	can	phosphorylate	each	
other,	 further	 activating	 JAK	 and	 allowing	 it	 to	 phosphorylate	 the	 receptor	 on	 target	
tyrosine	 residues	 (Rane	 and	 Reddy,	 2002).	 Then,	 STAT	 proteins	 bind	 to	
phosphotyrosine	residues	on	the	receptor	proteins	and	are	phosphorylated	by	JAK	on	a	
single	tyrosine	residue	around	residue	700	of	their	750850	amino-acid	sequences.	Once	
phosphorylated,	 STAT	 proteins,	 which	 are	 latent	 in	 the	 cytoplasm,	 become	 activated	
and	a	dimer	 is	 formed	which	 is	an	active	transcription	factor.	 It	 travels	to	the	nucleus	
where	 it	 binds	 to	 consensus	 DNA-recognition	 motifs,	 called	 gamma-activated	 sites	
(GAS),	 in	 the	 promoters	 of	 cytokine-inducible	 genes,	 resulting	 in	 gene	 transcription	











of	 a	 transcription	 pathway.	 Cytokine-receptor	 interaction	 triggers	 sequential	 tyrosine	





amino	 acids,	 Src-homology	 2	 (SH2),	 SH3	 domains,	 pleckstrin	 homology	 domain	 (PH),	












and	 establish	 tumours	 (Bromberg	 and	 Jr,	 2000).	 IFNγ,	 IFNα,	 IFNβ	 and	 IL-27	 activate	
STAT1	 (Perona-Wright	 et	al.,	2010).	 IL-21	 preferentially	 activates	 STAT1	 and	 STAT3,	
which	 is	mediated	by	Y510	 tyrosine	 in	 the	cytoplasmic	domain	of	 IL-21R	(Zeng	et	al.,	
2007).	 STAT1	 deficiency	 rather	 than	 the	 absence	 of	 both	 IFNγ	 and	 IFNα/β	 receptors	
results	 in	 pronounced	 impairment	 of	 NK	 cell	 function,	 demonstrating	 the	 IFN-
independent	roles	of	STAT1	for	the	NK	cell	response	(Lee	et	al.,	2000)	.	
STAT2	
The	main	 function	 of	 STAT2	 is	 its	 role	 in	 IFNα/β	 signalling,	where	 it	 complexes	with	
STAT1	and	either	heterodimerises	by	associating	with	DNA	binding	protein	IRF-9	and	
forming	 ISGF-3	 (IFN-stimulated	 gene	 factor	 3),	 or	 they	 can	 form	 STAT1	 homodimers	






STAT3	 plays	 an	 important	 role	 in	 the	 immune	 system,	 including	 regulation	 of	 steady	




which	 is	 associated	 with	 bacterial	 infections	 (Alonzi	 et	 al.,	 2001).	 It	 is	 an	 important	
signalling	molecule	in	Th17	differentiation	and	when	activated	by	both	IL-6	and	IL-23,	




an	 IL-6	deficient	environment	 (Korn	et	al.,	2007).	Kortylewski	 and	Yu	 showed	 for	 the	
first	 time	 that	 STAT3	 deletion	 in	 the	 haematopoietic	 compartment	 improves	 tumour	
immune	 surveillance	 (Kortylewski	 et	 al.,	 2005).	 STAT3	 deletion	 in	 NK	 cells	 affect	
tumour	 cells,	 increasing	 the	 level	 of	 perforin	 and	 granzymes	 B,	 demonstrating	 an	
inhibitory	role	 for	STAT3	 in	NK	cell	dependent	 tumour	surveillance	by	binding	 to	 the	
IFNγ	promoter	and	interfering	with	STAT	driven	transcription	(Gotthardt	et	al.,	2014).	
Furthermore,	 it	 has	 been	 shown	 that	 STAT3	 is	 aberrantly	 activated	 in	 a	 type	 of	





It	 is	mainly	 phosphorylated	 by	 the	 IL-12	mediated	 signalling	 pathway	 in	 T	 cells,	 but	
STAT4	 can	 also	 be	 activated	 by	 IFNγ	 stimulation,	 which	 has	 only	 been	 observed	 in	
human	cells	(Ho	et	al.,	1996).	The	phenotype	of	STAT4	deficient	mice,	in	most	respects,	
is	 similar	 to	 mice	 lacking	 the	 IL-12	 or	 IL-12R	 subunit,	 having	 impaired	 Th1	
differentiation,	IFNγ	production,	and	cell-mediated	immunity	(Wurster	et	al.,	2000).	
STAT5	
It	 has	 been	 demonstrated	 that	 STAT5	 is	 a	 critical	 positive	 factor	 that	 promotes	 HSC	
fitness	 and	multilineage	haematopoiesis	 (Snow	et	al.,	2002).	 STAT5	 is	 required	 in	 the	
earliest	stages	of	differentiation	from	the	lymphomyeloid	repopulating	HSCs	(Bunting	et	
al.,	2002).	It	also	has	a	role	in	the	regulation	of	T	cell	proliferation	and	its	absence	leads	





are	 characterised	 by	 defects	 in	 responses	 to	 granulocyte	 macrophage	 colony	
stimulating	 factor	 (GM-CSF)	 and	 have	 loss	 of	 Prl-mediated	 mammary	 gland	








TGF-β-mediated	 Foxp3	 induction	 by	 binding	 to	 the	 Foxp3	 promoter,	 which	 can	 be	
reverted	 by	 retinoic	 acid	 and	 lead	 to	 iTregs	 increase	 (Takaki	 et	 al.,	 2008).	 This	








in	 vivo	 (Wang	 et	 al.,	 2008).	 The	 IFNγ	 induced	 increase	 in	 the	 expression	 of	 an	 anti-
SMAD,	Smad7,	through	the	JAK1/STAT1	pathway	effectively	suppresses	TGFβ-mediated	
Smad3	 phosphorylation,	 preventing	 translocation	 of	 Smad3-Smad4	 complex	 to	 the	
nucleus,	nuclear	accumulation	of	Smad3	and	the	activation	of	TGF-β	 responsive	genes	
(Ulloa	et	al.,	1999).	 Integrins,	 such	 as	 transmembrane	 receptors	 that	 can	mediate	 cell	
adhesion	 to	matrix	molecules,	 can	 control	 serine-threonine	 kinase	 protein	 kinase	 C	 ε	
(PKCε)	 phosphorylation	 and	 IFNγ-induced	 STAT1	 phosphorylation	 is	 suppressed	 in	




It	 is	 long-lived,	 slowly	 developing	 and	 highly	 evolved	 antigen-specific	 protective	
response	 composed	 of	 cell-mediated	 and	 antibody	 production,	 which	 can	 show	 an	
extraordinary	 different	 range	 of	 specificity	 (Tosi,	 2005).	 There	 is	 fundamental	 link	
between	innate	and	adaptive	immunity	and	the	magnitude	and	quality	of	the	adaptive	
immune	 response	 is	 hugely	 dependent	 on	 signals	 derived	 from	 innate	 immunity	
(Tough,	2002).	
1.4.1	T	cell	development	
T	 cells	 develop	 from	 progenitors	 derived	 from	 the	 pluripotent	 haematopoietic	 stem	
cells	 in	 the	 bone	marrow.	 Lymphoid	 precursors	migrate	 from	 the	 bone	marrow	 and	
blood	 into	 the	 thymus,	 where	 they	 receive	 a	 signal,	 most	 probably	 from	 the	 stromal	
cells,	that	is	transduced	through	the	Notch	1	receptor	to	switch	on	specific	genes.	Notch	
1	instructs	the	lymphoid	precursor	to	become	a	T	lymphocyte	rather	than	B	lymphocyte	
(Owen	 et	 al.,	 2013).	 The	 mentioned	 progenitor	 cells	 undergo	 several	 stages	 of	
development	 to	 become	 mature	 T	 cells.	 These	 lymphoid	 precursors	 lack	 surface	
molecules	(CD4/CD8)	and	their	receptor	genes	are	unarranged	and	this	is	called	double	
negative	stage,	which	can	be	divided	into	four	stages	based	on	the	surface	expression	of	
CD44	 and	 CD25	 (Germain,	 2002).	 During	 DN1,	 CD44	 is	 expressed,	 but	 CD25	 is	 not	






which	 pre-TCRs	 proliferate.	 Moreover,	 allelic	 exclusion	 occurs,	 in	 which	 T	 cells	 fully	
rearrange	and	express	a	TCRβ	chain	from	only	one	of	their	two	TCR	alleles,	so,	β	chain	
couples	with	 pre-T	 α	 chain	 and	 rapid	 proliferation	 occurs	 in	 the	 sub-capsular	 cortex	
(Murphy,	2012).		
Afterwards,	thymocytes	go	through	the	development	of	CD4+	and	C8+,	known	as	double	
positive	 stage,	 which	 reside	 in	 the	 thymic	 cortex	 and	 are	 the	 most	 abundant	
subpopulation	in	the	thymus.	In	this	step,	young	DP	thymocytes	successfully	rearrange	
and	 express	 a	 TCRα	 chain,	 which	 associates	 with	 the	 already	 produced	 TCRβ	 chain,	
taking	 the	 place	 of	 the	 surrogate	 TCRα	 chain,	 which	 is	 no	 longer	 actively	 expressed	
(Owen	et	al.,	2013).	
Then,	 these	 lymphocytes	 receive	 a	 survival	 signal	 through	 undergoing	 positive	 or	
negative	 selection,	 but	most	 lymphocytes	 (98%)	never	meet	 these	 criteria	 and	die	by	
apoptosis	 within	 the	 thymus.	 The	 majority	 fail	 positive	 selection	 and	 their	 receptor	
interacts	so	poorly	with	self-MHC	molecules	that	they	die	by	a	process	known	as	death	
by	neglect.	Positive	 selection	 is	a	process,	which	selects	 for	 those	 thymocytes	bearing	
receptors	 capable	 of	 binding	 self-MHC	 molecules.	 These	 self-MHC	 molecules	 present	
self-peptides,	 which	 are	 typically	 arrived	 from	 intracellular	 or	 extracellular	 proteins	
that	are	degraded	and	interact	with	MHCI/II	to	receive	the	vital	signal	and	differentiate	
(Murphy,	2012).	Negative	selection	will	remove	thymocytes	(5%)	in	medulla	that	bear	
TCRs	 capable	 of	 strongly	 binding	 with	 self-MHC	 peptides	 and	 errors	 in	 negative	
selection	are	responsible	for	autoimmune	disorders	(Murphy,	2012).		
Afterwards,	 positively	 selected	 thymocytes	 must	 decide	 whether	 to	 join	 the	 CD8+	
cytotoxic	T	cell	 lineage	or	the	CD4+	helper	T	cell	 lineage.	So,	 two	models	are	proposed	
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for	 lineage	 commitment	 (Figure	 1.1).	 First	 in	 the	 instructive	 model,	 TCR/CD4	 and	
TCR/CD8	 co-engagement	 generate	 unique	 signals	 that	 directly	 initiate	 distinct	
developmental	programmes.	 If	a	 thymocyte	generated	a	TCR	with	an	affinity	 for	MHC	
class	I,	the	TCR	and	CD8	would	bind	the	MHC	class	I	together,	generating	a	signal	that	
specifically	 initiates	a	programme	to	silence	CD4	expression	and	 induce	expression	of	
genes	 specific	 for	 cytotoxic	 T	 cell	 lineage	 function.	 Likewise,	 TCR/CD4	 molecules	
generate	distinct	intracellular	signals	when	they	co-engage	with	MHC	class	II	and	makes	
CD8	to	lose	its	expression	(Germain,	2002).	
By	 contrast,	 in	 the	 stochastic	 model,	 positively	 selected	 thymocytes	 randomly	
downregulate	CD4	or	CD8	and	only	those	cells	that	express	the	correct	co-receptor,	the	
ones	that	can	engage	MHC	with	the	TCR,	generate	a	TCR	signal	strong	enough	to	survive	
to	mature,	 if	 the	 cell	 doesn’t	 receive	 a	 signal	 through	 the	 correct	 co-receptor,	 it	 dies.	






coreceptors.	  According to the one-step instructive model, coengagement of MHC class I–
restricted TCR and CD8 or MHC class II–restricted TCR and CD4 induces alternative signals 
that promote specific CD8 or CD4 lineage programs of gene expression and lead directly to 
silencing of the inappropriate coreceptor. In contrast, the stochastic-selective model involves two 
steps: a random lineage choice, and selection of thymocytes whose coreceptor expression 




Once	 a	 thymocyte	 successfully	passes	 through	 the	 selection,	 it	 leaves	 the	 thymus	 and	
those	mature	T	 cells	 that	 exit	 the	 thymus	 are	 referred	 to	 as	 recent	 thymic	 emigrants	
(RTEs),	which	 are	 self-restricted,	 self-tolerant	 and	 single	 positive.	 Final	maturation	 is	















proliferation,	 CD28,	 is	 a	 glycoprotein	 presented	 on	 T	 lymphocytes,	 which	 as	 a	 co-
stimulatory	 molecule	 binds	 to	 B7-1	 (CD80)	 and	 B7-2	 (CD86)	 ligands	 on	 antigen	
presenting	cells,	 finally	enhancing	 transcription	and	stability	of	 IL-2	mRNA,	 thereby	T	
cells	can	proliferate	and	produce	IL-2,	as	a	T	cell	growth	factor	(Linsong	Li	et	al.,	1999).	
In	 contrast,	 interruption	 in	 the	 CD28	 pathway	 not	 only	 suppresses	 the	 immune	
response	but	also	induces	antigen-specific	tolerance	(J.	et	al.,	1996).	
CD4	 can	 play	 a	 central	 role	 in	 immune	 protection	 via	 its	 ability	 to	 help	 B	 cells	make	
antibody,	 recruit	 polymorphonuclear	 phagocytes	 to	 the	 site	 of	 infection,	 induce	
macrophages	to	develop	increased	microbicidal	activity	and	producing	chemokines	and	
cytokines	to	orchestrate	the	full	immune	responses	(Zhu	and	Paul,	2008).	During	their	
first	 interaction	with	 antigens	 and	pattern	 of	 signals	 they	 receive,	 CD4	T	 cells	 can	 be	
differentiated	 into	 four	 populations	 including,	 Th1,	 Th2,	 Th17	 and	 regulatory	 T	 cells	
(Zhu	et	al.,	2010).	
Th1	cells	mediate	 immune	responses	against	 intracellular	microorganisms,	with	T-bet	
being	 the	 master	 transcriptional	 factor	 and	 Th1	 principal	 cytokine	 production	 being	











Figure	 1.7	 CD4	 T	 helper	 cell	 lineage	 fate	 and	 function.	 It	 summarises	 major	 set	 of	 CD4	 T	 cells,	








several	 stages	 and	 in	 these	 stages,	 multipotent	 progenitors	 (MPP)	 differentiate	 into	
lymphoid	progenitors	and	B	cell-restricted	progenitors	originate	 from	early	 lymphoid	
progenitors,	 followed	by	common	 lymphoid	progenitors	(CLP),	pro-B	cells,	pre-B	cells	
and	 immature	 B	 cells	 (Figure	 1.8)	 (Ichii	 et	 al.,	 2014).	 Immunoglobulin	 gene	
rearrangements	are	required	for	the	process	of	B	lymphopoiesis	and	mature	B	cells	as	
well	 as	 T	 cells.	 The	 activation	 of	 recombination	 enzymes,	 such	 as	 recombination-
activating	 gene	 (RAG-1	 and	 RAG-2)	 and	 terminal	 deoxynucleotidyl	 transferase,	
promotes	the	D	to	J	and	V	to	DJ	rearrangements	in	the	Ig	heavy	(IgH)	chain	locus	during	
the	differentiation	from	CLP	to	pro-B	stage.	Bone	marrow	stromal	cell-derived	IL-7	is	a	





αIg-B	 heterodimer	 to	 form	 the	 pre-B	 cell	 receptor,	 only	 pre-B	 cells	 that	 are	 able	 to	
express	membrane	bound	μ heavy	chain	 in	association	with	surrogate	 light	chain	are	
able	to	proceed	along	the	maturation	pathway	(Owen	et	al.,	2013).	
In	 the	 next	 stage,	 pre-B	 cells	 develop	 into	 mature	 B	 cells,	 which	 show	 complete	
membrane	of	IgM	on	the	cell	and	the	κ	and	λ	chain	is	also	attached	to	μ.	Furthermore,	
immature	B	cells	 react	with	antigens	with	high	avidity,	 such	as	polyvalent	antigens	 in	
bone	marrow,	leading	to	apoptosis	rather	than	activation;	this	property	is	important	for	
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negative	 selection	 of	 B	 cells	 that	 are	 specific	 for	 innate	 antigens	 available	 in	 bone	
marrow.	By	 contrast,	 immature	B	 cells	 that	do	not	bind	 self-antigens	express	D	 chain	




Figure	 1.8	 B	 cell	maturation	 stages	 and	 their	 cell	 surface	markers.	B	cell	 lymphocytes	arise	 from	





the	 bone	 marrow	 and	 complete	 their	 maturation	 in	 the	 spleen	 before	 migration	 to	
lymphatic	 organs.	 After	 mature	 B	 cells	 migrate	 to	 secondary	 lymphoid	 organs,	 they	
proliferate	and	differentiate	in	the	presence	of	antigen.	There	are	two	main	procedures	
at	 this	 level,	 somatic	 hypermutation	 and	 immunoglobulin	 isotype	 switching.	 Somatic	
hypermutation	occurs	in	variable	antibody	genes,	 in	both	heavy	and	light	chain	genes,	
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leading	 to	 affinity	maturation	 (the	 affinity	 of	 binding	 the	 antibody	 to	 antigen),	 while	
changing	the	constant	heavy	chain	occurs	in	isotype	switching	(Murphy,	2012).		
B	 cell	 activation	 is	 enhanced	 through	 the	 activity	 of	 CD21,	 a	 surface	 receptor	 in	 a	
complex	with	surface	proteins	CD19	and	CD81	(all	three	are	collectively	known	as	the	B	
cell	co-receptor	complex).	Once	a	B	cell	encounters	its	cognate	antigen	and	receives	an	





Figure	 1.9	 The	 interface	 between	 innate	 and	 adaptive	 immunity.	 Innate	 immune	 system	
components	 recognise	 the	 microbes	 and	 help	 with	 the	 successful	 removal	 of	 pathogens.	 These	
include	specialised	receptors	on	NK	cells,	complement	system,	TLRs	that	are	expressed	on	myeloid	
and	 lymphoid	 cells,	 which	 recognise	 specific	 microbially	 derived	 molecular	 structures.	 A	 well	




preserve	 self-tissues	 while	 allowing	 effective	 responses	 against	 infections.	 In	
autoimmunity,	dysregulated	immune	responses	of	the	body	occur	against	its	own	cells	
and	 tissues.	 Typically,	 autoimmune	 diseases	 are	 multi-etiological	 entities,	 where	
environmental,	 genetic	 abnormalities,	 hormonal	 defects	 along	 with	 derailed	
immunoregulatory	processes	lead	to	the	development	of	the	disease	(Nagy	et	al.,	2015).	
Therefore,	 faulty	 tolerance	 mechanism,	 imbalance	 of	 pro	 and	 anti-inflammatory	
cytokines,	abnormal	auto-antigen	scavenging	machinery	and	antigen	presentation	can	
contribute	to	the	development	and	continuation	of	autoimmune	diseases	(Ermann	and	
Fathman,	 2001).	 Altered	 survival	 of	 T	 cells	 and	 defects	 in	 the	 inhibitory	 signalling	
pathways	of	T	cells	is	one	of	the	major	factors	that	can	contribute	to	autoimmunity	and	
they	are	referred	as	T	cell-mediated	autoimmune	disease,	such	as	rheumatoid	arthritis	
(RA),	multiple	 sclerosis,	 type	 1	 diabetes,	 inflammatory	 bowel	 disease	 (IBD),	 systemic	
lupus	erythematosus,	Sjogren’s	syndrome	and	psoriasis	(Wu	et	al.,	2012).		
Death	receptor	Fas	(CD95)	is	vital	in	T	cell	deletion	and	if	self-reactive	T	cell	deletion	is	
disrupted,	 autoimmunity	 might	 also	 arise,	 whereas	 if	 self-antigens	 are	 presented	 on	
activated	mature	 APCs,	 this	 can	 lead	 to	 activation	 of	 self-reactive	 T	 cells	 resulting	 in	
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autoimmunity	(Ohashi,	2002).	Lack	of	the	receptor	tyrosine	kinases,	such	as	Tyro3,	Axl	
and	Mer,	 that	are	 regarded	as	negative	 regulators	of	APC	activation	can	contribute	 to	
APC	 activation	 and	 development	 of	 broad-spectrum	 autoimmunity	 (Lu	 and	 Lemke,	
2001).	
Enhanced	activation	of	the	PI3K-PKB	pathway	and	in	particular,	changes	in	the	activity	
of	 the	 PI3K	 subunit	 p65PI3K,	 PTEN	 and	 PKB	 alter	 Fas-mediated	 apoptosis,	 thereby	







In	 the	absence	of	Cbl-b,	a	 cytoplasmic	protein	 that	works	as	a	negative	regulator	of	T	
cell	 signalling,	 IL-2	 production	 is	 enhanced	 after	 TCR	 stimulation,	 indicating	
predisposition	 towards	 autoimmunity,	 with	 symptoms	 such	 as	 multi-organ	
inflammation	 and	 production	 of	 autoantibodies,	 demonstrating	 the	 role	 of	 Cbl-b	 as	
negative	regulator	of	mature	T	cell	activation	(Ohashi,	2002).		
Abnormal	activation	of	effector	subsets	of	CD4+	T	helper	cells,	including	Th1	and	Th17,	
play	 a	 key	 role	 in	 mediating	 many	 aspects	 of	 organ-specific	 autoimmune	 diseases.	
Furthermore,	 Th1	 and	 Th17	 can	 induce	 production	 of	 inflammatory	 chemokines	 and	





organ-specific	 autoimmune	 disease,	 a	 mechanism	 known	 as	 molecular	 mimicry	
(Oldstone,	1987,	Oldstone	et	al.,	1991).	
In	 addition,	 Tregs	 are	 important	 and	 play	 a	 crucial	 role	 in	 immune	 homeostasis,	
maintaining	 peripheral	 tolerance	 for	 self-tissues	 to	 prevent	 autoimmunity.	 In	




extrathymically	 upon	 antigen	 exposure,	 which	 can	 complement	 tTregs	 to	 establish	
tolerance	by	participating	locally	at	the	site	of	inflammation	to	control	immunity.	One	of	




members:	 Egr1	 (Krox-24/NGFI-A),	 Egr2	 (Krox-20),	 Egr3	 (NGFI-3/Pilot)	 and	 Egr4	
(NGFI-C).	All	members	share	three	cyc2-Hys2	zinc	fingers	that	bind	to	the	cognate	GC-
rich	 consensus	 DNA	 binding	motif	 of	 28-30	 amino	 acids	 (Figure	 1.10)	 (Poirier	 et	 al.,	




Egr1	 has	 a	 regulatory	 role	 in	 T	 cell	 proliferation	 and	 is	 rapidly	 induced	 after	 IL-2	
stimulation	(Perez-Castillo	et	al.,	1993).	It	binds	to	the	regulatory	ZIP	elements	and	acts	
as	a	potent	coactivator	for	the	nuclear	factor	of	activated	T	cells	(NFATc)	within	the	IL-2	
promoter	 leading	 to	 IL-2	 transcription	 (Decker	 et	al.,	1998).	 Egr1	 also	 plays	 a	 role	 in	
thymocyte	development	and	by	enhancing	expression	of	anti-apoptosis	molecule	bcl-2	
and	 Id3	 inhibitor,	 it	 promotes	 positive	 selection	 of	 both	 CD4	 and	 CD8	 single	 positive	
cells	 (Bettini	 et	 al.,	 2002).	 Id3	 promotes	 thymocyte	 maturation	 and	 during	 positive	
selection,	 Id3	 expression	 is	 upregulated	 in	 response	 to	 TCR	 signalling	 (Rivera	 et	 al.,	




muscle-spindle	 development	 (O'Donovan	 et	al.,	1999).	 Egr4	was	 initially	 identified	 in	












Egr2	 and	 Egr3	 are	 expressed	 in	 selected	 stages	 of	 B	 and	 T	 cell	 development	 and	 are	





suppressing	 NAB2	 and	 Egr1	 expression	 (Collins	 et	 al.,	2008).	 NAB2	 as	 a	 coactivator	
collaborates	 with	 Egr1,	 promoting	 IL-2	 production	 and	 T	 cell	 function	 (Collins	 et	 al.,	
2006).	 Cells	 overexpressing	 Egr2	 and	 Egr3	 showed	 increased	 Cbl-b,	 and	 T	 cells	 from	




cells	 to	 stimulation,	 resulting	 in	 restored	 state	 proliferation	 and	 IL-2	 production	 in	
anergic	cells,	indicating	the	role	of	Egr2	role	in	conferring	the	anergic	state	(Harris	et	al.,	
2004).	
Egr2	 and	 Egr3	 are	 crucial	 for	 the	 control	 of	 inflammation	 and	 antigen-induced	
proliferation	 of	 B	 and	 T	 cells.	 In	 this	 regard,	 Egr2	 and	 3	 deficient	 mice	 led	 to	 the	
diminished	 activation	 of	 SOCS1	 and	 SOCS3,	 resulting	 in	 enhanced	 activation	 levels	 of	
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IFN-γ	 and	 Th17	 polarisation	 respectively,	 suggesting	 a	 fundamental	 role	 of	 Egr2	 and	
Egr3	 in	 limiting	 immunopathology	during	productive	adaptive	 immune	responses	and	
preventing	 the	 development	 of	 autoimmune	 disease	 (Figure	 1.11)	 (Li	 et	 al.,	 2012).	
SOCS1	 and	 SOCS3	 deficiency	 leads	 to	 activation	 of	 peripheral	 T	 cells,	 resulting	 in	 the	
development	 of	 inflammatory	 disease	 (Chong	 et	 al.,	 2005,	 Croker	 et	 al.,	 2004).	 The	
suppressor	 of	 cytokine	 signalling	 (SOCS)	1	 and	 SOCS3	negatively	 regulate	 STAT1	 and	
STAT3,	 the	 major	 signal	 transducers	 pathways,	 respectively,	 which	 control	 the	
differentiation	 and	 development	 of	 Th1	 and	 Th17	 respectively	 (Ramgolam	 and	
Markovic-Plese,	2011).	A	recent	study	identified	that	Egr2	and	3	are	potent	antagonists	

















CD44high	 T	 cells	 are	 hyperactive	 in	 vivo	 in	 Egr2/3	 deficient	 mice,	 resulting	 in	
development	 of	 a	 late	 onset	 lupus-like	 autoimmune	 disease	 characterised	 by	 severe	
glomerulonephritis,	skin	 lesions,	hair	 loss,	significantly	 increased	 infiltration	of	T	cells	
into	 multiple	 organs,	 enhanced	 total	 serum	 Ig	 and	 accumulation	 of	 IFNγ	 and	 IL-17	
producing	CD4+	T	cells	in	comparison	to	age-matched	WT	mice	counterparts.	Thus,	this	
reflected	 a	 vital	 intrinsic	 role	 of	 Egr2,	 not	 only	 in	 inflammation	 and	 proliferation	 of	
effector	T	cells,	but	also	 in	prevention	of	developing	a	 lupus-like	autoimmune	disease.	
CD44high	 is	 regarded	 as	 a	 marker	 for	 memory	 and	 effector	 T	 cells	 (Schumann	 et	 al.,	
2015).	 The	 pathogenesis	 of	 systemic	 lupus	 erythematosus	 is	 closely	 related	 to	 the	
significant	production	of	pro-inflammatory	chemokines	and	cytokines	 IL-17	and	IFN-γ	
(Crispin	et	al.,	2008).	Moreover,	another	study	demonstrated	that	in	treatment	for	SLE	
through	 downregulation	 of	 Akt	 phosphorylation,	 diminished	 expression	 of	 Egr2	 and	
Egr3	 was	 ameliorated	 by	 hCDR1	 peptide,	 which	 led	 to	 down-regulated	 IL-2	 mRNA	
expression	 and	 IFNγ	 secretion,	 but	 enhanced	expression	 levels	 of	E3	 ligase	Cbl-b	 and	
TGFβ,	 inducing	 anergy,	 thereby	 demonstrating	 the	 crucial	 role	 of	 Egr2	 and	 Egr3	 as	







Fas	 ligand	 (Fas	 L)	 regulatory	 element	 in	 the	 FasL	 promoter	 and	 its	 transcription	 is	
induced	 after	 TCR	 activation	 via	 the	 NFAT	 dependent	 induction	 of	 Egr2	 and	 Egr3	
(Rengarajan	 et	 al.,	2000).	 FasL	 is	 a	 transmembrane	 protein	 belonging	 to	 the	 tumour	









2011).	Thus	 far,	 it	 has	been	demonstrated	 that	Egr2	 is	 induced	by	 the	TCR	 signalling	
pathway	 (Shao	 et	 al.,	 1997,	 Carter	 et	 al.,	 2007,	 Seiler	 et	 al.,	 2012,	 Zhu	 et	 al.,	 2008).	
Rengarajan	 et	 al.	 (2000)	 reported	 that	 Egr2	 is	 a	 NFAT-regulated	 target	 gene,	 the	
expression	 of	 which	 was	 severely	 impaired	 in	 NFATp-/-	 and	 NFAT4-/-	 mice,	 whereas	
Egr2	was	 transactivated	 by	 NFATp	 overexpression.	 Other	 reports	 also	 confirmed	 the	
regulatory	role	of	NFAT	in	Egr2	expression	in	T	cells	(Lazarevic	et	al.,	2009).	Although	




2008).	 Moreover,	 Ly	 108,	 a	 SLAM	 family	 receptor,	 increased	 co-stimulation	 and	
sustained	CD3-induced	Egr2	expression	in	developing	thymocytes	(Dutta	et	al.,	2013).	
A	recent	study	showed	that	Egr2	can	be	induced	through	CD26	mediated	co-stimulation	
along	with	 the	preferential	production	of	 IL-10	 in	CD4+	T	 cells.	 It	has	been	 suggested	
that	not	only	NFAT	but	also	Raf-MEK-ERK	signalling	is	involved	in	the	induction	of	Egr2	
expression	 (Hatano	 et	 al.,	 2015).	 MAPK/ERK	 signalling	 association	 with	 the	 Egr2	
induction	 has	 been	 reported	 in	 osteoprogenitors	 through	 the	 stimulatory	 effect	 of	
epidermal	 growth	 factor	 receptor	 (EGFR)	 (Chandra	 et	 al.,	2013),	 suggesting	 that	 the	
ERK	 signalling	 pathway	 is	 also	 associated	with	 the	 induction	 of	 Egr2	 expression	 in	 T	
cells.	
1.7	Tumour	immunosurveillance		
Cancer	 is	defined	as	 the	accumulation	of	numerous	genetic	alterations	and	 the	 loss	of	
normal	 cellular	 regulatory	 processes,	with	 the	 initiation	 of	 several	 events	 proceeding	
and	expanding	effective	anti-cancer	immune	responses	against	cancer	cells.	In	the	first	
step,	after	oncogenesis,	neoantigens	are	released	and	captured	by	dendritic	cells	(Tian	
et	 al.,	 2011).	 In	 the	 processing	 step,	 immunologic	 signals	 such	 as	 pro-inflammatory	
cytokines	and	 factors	are	 released,	 then	captured	antigens	are	presented	by	dendritic	




the	 immune	 response	 in	 the	 subsequent	 revolutions	 of	 the	 cycle	 (Chen	 and	Mellman,	
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2013).	The	cancer	cycle	 in	cancer	patients	does	not	perform	optimally,	 in	this	process	
tumour	 antigens	 may	 not	 be	 recognised,	 dendritic	 cells	 and	 T	 cells	 may	 not	 detect	




in	 cancer	 immunotherapy	and	different	mechanisms,	 including	conserved	or	acquired	
somatic	mutations	 and	T	 cell	 exhaustion	are	 involved	 in	making	dysfunctional	T	 cells	
(Speiser	 et	 al.,	 2016).	 Adoptive	 cell	 therapy	 (ACT)	 using	 autologous	 TILs	 with	 anti-
tumour	activity	has	emerged	to	be	the	most	effective	therapy	in	metastatic	melanoma	in	
experimental	 animals	 as	 well	 as	 cancer	 patients	 (Rosenberg	 et	 al.,	 2008).	 The	
generation	 of	 a	 tumour	 specific	 T	 cells	 by	 autologous	 lymphocytes	 from	 peripheral	
blood	 using	 a	 retrovirus	 that	 encodes	 TCR	 can	 mediate	 metastatic	 melanoma	
regression,	 so	 genetically	 engineered	 lymphocytes	 have	 the	 potential	 to	 be	 used	
therapeutically	for	cancer	(Morgan	et	al.,	2006).	
Furthermore,	 fundamental	T	 cell	 unresponsiveness	 in	 advanced	 tumours	 is	 driven	by	
TGF-β	 signalling	 through	 Smad2/3	 transcriptional	 factors,	 which	 in	 turn	 upregulate	
Foxp1.	This	suppresses	CD8+	T	cell	proliferation	and	upregulation	of	Granzymes	B	and	
IFNγ	in	response	to	tumour	antigens	(Stephen	et	al.,	2014,	Delisle	et	al.,	2013).	Stephen	
et	al.	(2014)	 showed	 that	 tumour-reactive	Foxp1	deficient	CD8+	T	 cells	have	 superior	
anti-tumour	 effector	 functions,	 which	 can	 induce	 the	 regression	 of	 aggressive	
established	 tumours.	 Among	 the	 various	 approaches	 to	 therapeutic	 anti-tumour	
immunity,	blockade	of	immune	checkpoints	has	shown	promising	results	and	different	
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studies	 have	 highlighted	 immune	 checkpoint	 pathways	 as	 a	 prominent	mechanism	of	









CTLA4,	 the	 first	 clinically	 targeted	 immune	 checkpoint	 receptor,	 is	 expressed	
exclusively	on	T	cells	where	 it	mainly	regulates	 the	amplitude	of	 the	early	stages	of	T	
cell	 activation.	 Primarily,	 CTLA4	 has	 a	 counteractive	 influence	 on	 the	 activity	 of	 the	
CD28,	 a	 T	 cell	 co-stimulatory	 receptor.	 It	 was	 demonstrated	 that	 CTLA4	 has	 a	much	
higher	 overall	 affinity	 for	 both	CD80	 and	CD86,	 hence	with	 CTLA4	 expression	 on	 the	
surface	of	T	cells	and	by	outcompeting	CD28	in	binding	CD80	and	CD86,	 it	diminishes	
the	activation	of	T	cells.	It	also	actively	delivers	inhibitory	signals	to	the	T	cell	(Rudd	et	
al.,	 2009).	 After	 tumour	 implantation,	 an	 endogenous	 anti-tumour	 immune	 response	
was	generated	 in	 the	animals	and	CTLA4	blockade	could	boost	endogenous	 response,	




enough	 immune	 response	 to	 decrease	 tumour	 growth	 and	 in	 some	 cases,	 eliminate	
established	tumours	completely	(van	Elsas	et	al.,	1999,	Leach	et	al.,	1996).	
PD-1	
The	 immune	 responses	 should	 be	 tightly	 regulated	 and	 during	 the	 inflammatory	
immune	response	to	infection,	PD-1	plays	a	major	role	in	limiting	the	activity	of	T	cells	
in	 peripheral	 tissues	 and	 restrict	 autoimmunity	 (Keir	 et	al.,	 2006).	 PD-1	 is	 expressed	
when	 T	 cells	 become	 activated	 and	 binds	 to	 one	 of	 its	 ligands,	 it	 suppresses	 T	 cells	
activation	 through	 inhibiting	 kinases	 that	 are	 involved	 in	 T	 cell	 activation	 via	 the	
phosphatase	SHP2.	In	a	similar	fashion	to	CTLA4,	PD-1	expression	is	highly	induced	on	
Treg	cells,	where	it	can	increase	their	proliferation	in	the	presence	of	ligand	(Keir	et	al.,	
2008).	 TReg	cells	 are	highly	 infiltrated	 into	 tumours	 that	 can	 further	 suppress	 effector	
immune	responses,	so	blockade	of	the	PD-1	pathway	can	revert	this	function,	enhancing	
anti-tumour	immune	responses	by	diminishing	the	number	and	suppressive	activity	of	
intra-tumoural	 Treg	 cells	 (Francisco	 et	 al.,	 2009).	 PD-1	 expression	 is	 also	 induced	 in	




the	 activity	 of	 NK	 cell	 in	 tumours	 and	 tissues,	 probably	 either	 indirectly	 or	 through	
direct	 effects	 on	 PD1+	B	 cells	 amplifying	 antibody	 production	 (Velu	 et	 al.,	 2009).	 A	
recent	 study	showed	 that	T	cell	 invigoration	of	 the	 tumour	burden	ratio	 is	associated	





PD-1	 is	 highly	 expressed	 on	TILs	 from	multiple	 cancers	 and	PD-1	 ligands	 are	 usually	











T	 cell	 immunoglobulin	 and	 mucin	 domain	 containing-3	 (TIM3)	 is	 encoded	 by	 the	
HAVCR2	 gene.	 It	 inhibits	 responses	 of	 T	 helper	 1	 (TH1)	 cell	 and	 TIM3	 antibodies	
enhance	 anti-tumour	 immune	 responses	 (Zhu	 et	 al.,	 2005).	 In	 animal	 models,	
coordinated	blockade	of	PD-1	and	TIM3	amplifies	anti-tumour	immunity	and	blockade	





The	 expression	 of	 B	 and	 T	 lymphocyte	 attenuator	 (BTLA)	 on	 activated	 virus-specific	
CD8+	T	 cells	 is	 relatively	 low,	 but	 it	 can	 be	 much	 higher	 on	 TILs	 from	 melanoma	
patients.	 BTLAhi	T	 cells	 are	 suppressed	 in	 the	 presence	 of	 its	 ligand,	HVEM.	 So,	 BTLA	
may	 be	 a	 pertinent	 inhibitory	 receptor	 for	 T	 cells	 in	 the	 tumour	 microenvironment	
(Lasaro	et	al.,	2011).	
	









Previous	 studies	have	demonstrated	 that	Egr2	 and	Egr3	 are	 vital	 for	 antigen-induced	
proliferation	 of	 B	 and	 T	 cells	 and	 the	 control	 of	 inflammation.	 Furthermore,	
investigation	of	lymphocyte	specific	Ege2	and	Egr3	double	knockout	mice	demonstrated	
the	indispensable	role	of	Egr2	and	Egr3	in	preventing	the	development	of	autoimmune	
disease	and	 limiting	 immunopathology	during	productive	adaptive	 immune	responses	
(Li	et	al.,	2012).	Moreover,	a	recent	study	by	our	group	demonstrated	an	important	role	
of	Egr2,	that	it	serves	as	a	checkpoint	controller	in	adaptive	immunity,	regulating	clonal	
proliferation	and	differentiation	 in	both	adaptive	and	homeostatic	 responses	 (Miao	et	
al.,	2017).	Based	on	the	previous	findings,	 it	was	hypothesised	that	Egr2/3	function	 is	
important	 for	 the	 potent	 anti-tumour	 immune	 response.	 Therefore,	 this	 study	













































All	 mice	 used	 in	 this	 study,	 including	 hCD2-Cre-Egr2-/-Egr3-/-	 mice	 and	 GFP	 Egr2	
knock-in	mice,	were	approved	under	the	authority	of	a	UK	Home	Office	project	licence.	
All	the	mice,	both	male	and	female,	were	used	at	7–8	weeks	of	age	and	were	maintained	
in	 the	biological	 services	unit,	Brunel	University,	 in	accordance	with	 the	guidelines	of	
the	committee	on	the	operation	of	animals,	Scientific	Procedures	Act	1986.		
2.1.2	Egr2	and	Egr3	knockout	mouse	model	





Cre,	 a	 recombinase	 enzyme	 initially	 found	 in	 the	 P1	 bacteriophage	 virus,	 which	 is	
attached	 to	 the	 CD2	 promoter	 in	 lymphocytes	 and	 recognises	 and	 cuts	 at	 these	 LoxP	
sites	 (Figure	2.1).	 LoxP	 sites	 are	34	base	pairs	 long	 and	 attract	 Cre	 to	 recombine	 the	
DNA	 surrounding	 them,	 so	hCD2-Cre	mice	 and	Egr2Loxp/LoxP	were	 crossed	 to	 generate	
CD2-specific	Egr2-/-	mice.	Then,	the	mice	were	backcrossed	with	a	C57BL/6	background	
to	 purify	 the	 line.	 Polymerase	 chain	 reaction	 (PCR)	 verified	 Cre	 and	 LoxP	 gene	
expression.	 Egr3	 knockout	mice	were	 generated	 using	 a	 neomycin	 cassette,	 with	 the	




















GFP-Egr2	 gene	was	 cloned	 into	 a	 pBabe	 vector	 to	 generate	 a	 construct	 in	which	 the	
target	gene	was	disrupted	with	the	neoR	gene	and	the	thymidine	kinase	tkHSV	gene	was	
located	 outside	 the	 target	 gene.	 This	 construct	 was	 introduced	 into	 the	 cultured	





cells	 were	 treated	 with	 gancyclovir	 and	 negatively	 selected	 so	 that	 non-homologous	
recombinants	 carrying	 the	 tkHSV	 gene	were	 killed.	 Those	 cells	 in	which	 the	 construct	
was	inserted	at	random	retained	the	expression	of	the	tkHSV	gene,	whereas	those	cells	in	
which	 the	 construct	 inserted	 by	 homologous	 recombination	 lost	 the	 tkHSV	 gene.	 The	
thymidine	 kinase	 gene	 from	 herpes	 simplex	 virus	 confers	 sensitivity	 to	 gancyclovir.	
Finally,	 homologous	 ES	 recombinants	 survive	 this	 selection	 scheme.	 Afterwards,	





Mice	were	 genotyped	prior	 to	use	 to	 confirm	excision	of	Egr2	 and	Egr3	genes	 and	 to	







buffer.	The	samples	were	vortexed	and	centrifuged,	 then	 incubated	 in	a	heating	block	





mice	 respectively	 to	 dilute	 them	 as	 necessary.	 PCR	 was	 performed	 to	 amplify	 the	
genomic	DNA	from	mice	samples	using	gene-specific	sense	and	antisense	primers.	This	
technique	 utilises	 Thermus	 aquaticus	 (Taq)	 polymerase,	 which	 is	 thermostable,	 to	
produce	 new	 copies	 of	 the	 gene	 of	 interest	 using	 dNTP,	which	 adds	 nucleotides	 into	
newly	synthesised	single-stranded	DNA.	PCR	mixtures	were	prepared	as	follows:	0.25	µl	


















EGR-2 KO - 
LoxP 
Sense - GTG TCG CGC GTC AGC ATG CGT 
Antisense - GGG AGC GAA GCT ACT CGG ATA CGG 
95°C for 5 min94°C 
for 40sec} 
65°C for 40sec }     
30 Cycles 
72°C for 40sec} 
72°C for 5min 






EGR-2 KO - 
Cre 
Sense - CCA ACA ACT ACC TGT TCT GCC G 
Antisense - TCA TCC TTG GCA CCA TAG ATC AGG  
95°C for 5min 
94°C for 40sec} 
56°C for 40sec }     
40 Cycles 
72°C for 40sec} 
72°C for 5min 
4°C for 10min 150bp 
Egr2 
Transgenic 
Sense - CCA CCA GTC TCA CTT CAG TTC C 
Antisense - CAG CTG CTG CAG AAA ACC ACT G 
95°C for 5min 
94°C for 40sec} 
55°C for 40sec }     
30 Cycles 
72°C for 40sec} 
72°C for 5min 
4°C for 10min 350bp 
Egr3 KO 
Sense - CTA TTC CCC CCA GGA TTA CC 
Antisense - TCT GAG CGG GCT GAA ACG 
Neo - GAT TGT CTG TTG TGC CCA GTC 
95°C for 5min 
94°C for 40sec} 
57°C for 40sec }     
35 Cycles 
72°C for 40sec} 
72°C for 5min 







Sense - GCTCAGTTCAAC CCC TCT CC 
 
Antisense - GGATTTTGTCTACGGCCTTG 
95°C for 3min 
95°C for 20sec} 
60°C for 20sec }     
30 Cycles 
72°C for 30sec} 
72°C for 5min 










moulding	blocks	and	 left	 to	 solidify	 for	20	minutes.	Then,	 samples	were	added	 to	 the	
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Spleens	 were	 harvested	 from	mice	 and	 homogenised	 in	 PBS	 using	 a	mesh.	 The	 cells	
were	 collected	 and	 centrifuged	 at	 1300	 rpm	 for	 5	minutes	 at	 room	 temperature.	 The	
supernatant	 was	 removed,	 and	 cells	 were	 resuspended	 in	 0.8%	 ammonium	 chloride	
solution	 and	 incubated	 at	 37°C	 for	 5	 minutes.	 The	 ammonium	 chloride	 creates	 an	
osmotic	potential	causing	 the	erythrocytes	 to	burst,	 thereby	depleting	red	blood	cells,	
while	maintaining	the	integrity	of	white	blood	cell	populations.	Then,	cells	were	washed	
up	 with	 PBS	 and	 centrifuged	 at	 1300	 rpm	 for	 5	 minutes	 and	 the	 supernatant	 was	
discarded	immediately.		
2.2.2	CD4+	T	cell	isolation	





rpm.	 The	 supernatant	was	 removed,	 and	 the	 pellet	 was	 resuspended	 in	 500	 µl–1	ml	
bead	buffer.	Magnetic	columns	were	calibrated	using	3	ml	bead	buffer	and	200	µl	of	the	
cells	were	added	to	 the	centre	of	 the	column	and	was	 left	 to	pass	 through	the	matrix.	
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were	 stimulated	 with	 a	 combination	 of	 phorbol	 12-myristate	 13-acetate	 (PMA)	 and	






























cell,	 including	 its	 size,	 density	 and	 complexity,	 at	 the	 single	 cell	 level	 based	 on	 the	
intensity	 of	 signals.	 In	 this	 respect,	 cells	 were	 labelled	 with	 antibodies	 bearing	
fluorochromes	 that	 attach	 to	 specific	 epitopes	 on	 the	 cells	 of	 interest	 enabling	 their	
detection.	 To	 analyse	 intracellular	 proteins,	 such	 as	 cytokines,	 and	 nuclear	 proteins,	
such	 as	 transcription	 factors,	 firstly	 cells	 were	 stained	 for	 cell	 surface	markers,	 then	
fixed	 with	 formaldehyde	 to	 allow	 for	 the	 stabilisation	 of	 the	 cell	 membrane	 and	
permeabilised	 to	 facilitate	 the	 entry	 of	 antibodies	 into	 the	 cell.	 Finally,	 the	 cells	 are	
passed	 through	a	 laser	 that	 sends	 the	 signal	 to	appropriate	detectors.	The	signals	are	
translated	electronically	so	that	the	user	can	interpret	the	data.	 In	this	study,	the	cells	


































The	 cells	 were	 stimulated	 with	 200	 ng/ml	 inomycine	 and	 200	 ng/ml	 PMA	 in	 the	
presence	of	1	µl/ml	Golgi	Stop	according	to	the	manufacturer’s	protocol.	The	following	
day,	cells	were	collected	and	washed	with	1X	PBS.	For	nuclear	or	intracellular	staining,	
cells	 were	 resuspended	 in	 1X	 fixation/permeabilisation	 buffer	 (EBioscience)	 and	
incubated	at	room	temperature	for	20	minutes.	Cells	were	centrifuged	and	resuspended	
in	 1X	 permeabilisation	 buffer	 and	 incubated	 for	 20	 minutes	 at	 room	 temperature.	
Following	 centrifugation,	 the	 cell	 pellet	 was	 resuspended	 in	 fluorescently	 labelled	
antibodies	 diluted	 in	 perm/wash	 buffer	 and	 incubated	 for	 20	 minutes	 at	 room	










mixture	was	 immediately	 added	 to	 the	 cells	 and	 they	were	 incubated	 overnight.	 The	




quantification	of	 luciferase	activity.	The	principle	 is	based	on	 the	measurement	of	 the	
light	 generated	 when	 the	 enzyme	 and	 substrates	 are	 combined.	 Firefly	 luciferase,	 a	
monomeric	 protein,	 encodes	 an	 enzyme	 that	 oxidises	D-luciferin	 using	ATP-Mg2+	as	 a	












and	 further	 vortexed	 for	 60	 seconds	 to	 aid	 the	 lysis	 process.	 At	 this	 stage,	 protein	
contents	were	released	by	the	 lysate	and	Bradford	assay	was	performed	to	determine	
the	protein	concentration	to	normalise	luciferase	readings	to	the	protein	concentration.	
Then,	 10	 µl	 of	 the	 lysate	 was	 added	 into	 a	 96-well	 plate,	 followed	 by	 50–100	 µl	 of	




this	 procedure,	 the	 Bradford	 reagent	 contains	 a	 dye	 named	 Brilliant	 Blue	 G,	 which	
complexes	with	proteins	 in	 the	 lysate.	The	protein-dye	complex	shifts	 the	absorbance	
from	495	nm	to	595	nm,	with	 the	amount	of	absorption	corresponding	 to	 the	protein	
content.	The	absorbance	was	measured	at	595	nm	on	Glomax	luminometer	(Promega).	
A	standard	curve	was	prepared	using	a	serial	dilution	of	bovine	serum	albumin	(BSA)	
from	0	mg/ml	 to	10mg/ml.	The	protein	 concentration	of	unknown	 samples	was	 then	









experiments,	 mice	 received	 1	 ×	 106	 B16	 melanoma	 tumour	 cells	 via	 subcutaneous	




mm)	 pieces,	 then	 incubated	 in	 dissociation	 buffer	 [RPMI	medium	 supplemented	with	




MACS	 positive	 selection	 kit	 (see	 section	 2.3.2)	 according	 to	 the	 manufacturer’s	
instructions.		
2.8	Statistical	analysis	


































mice,	 CD2-Egr2/3-/-	 mice	 were	 obtained	 by	 breeding	 CD2-Egr2-/-	 with	 Egr3-/+	









showed	homozygous	Egr2	LoxP,	with	 an	upper	band	 size	of	 210	bp	and	Cre	positive,	
with	a	band	size	of	150	bp	(Figure	3.1,	A).	Egr2	can	be	heterozygous	if	loxp	results	show	
both	upper	 and	 lower	 bands	 at	 210	bp	 and	195	bp	 respectively,	 however	 to	 have	 an	
Egr2	KO	mouse,	it	is	important	that	it	has	the	Cre	genes.	Secondly,	the	Egr3	neo	product	
that	 disrupts	 the	 Egr3	 gene	 was	 used	 to	 generate	 Egr3-/-	mice.	 This	 product	 has	 the	
possibility	 of	 2	 bands,	with	 the	homozygous	 completely	 knocking	out	Egr3	 at	 800	bp	
and	the	heterozygous	being	only	party	knocked	out	at	800	bp	and	400	bp	(Figure	3.1,	
























































Figure	 3.1	 Genotyping	 of	 CD-2	 specific	 Egr2-/-	 and	 Egr3-/-	 mice.	 (A)	 CD-2	 specific	 homozygous	
deletion	 of	 Egr2	 in	 mice	 expressing	 only	 LoxP	 homozygous	 bands	 and	 Cre	 bands	 (B)	 Egr3	
homozygous	deletion	were	those	that	expressed	neomycin-resistant	upper	bands.	Lane	1	is	Egr2	and	
Egr3	heterozygous;	lane	2,	3,	6	are	Egr2	homozygous	and	Egr3	heterozygous;	lane	4,	5	are	Egr2	and	




In	 addition	 to	 the	 phenotyping	 of	 the	 CD2-Egr2/3	 knockout	mice,	 the	 genotypes	 and	
phenotype	of	GFP-Egr2	knock-in	mice	were	analysed	according	to	our	reports	(Miao	et	
al.,	2017).	 PCR	 genotyping	 results	 showed	 an	 upper	 band	 of	 854	 bp	 in	 the	 GFP-Egr2	
homozygous	mouse	and	 lower	bands	at	119	bp	 indicated	that	GFP-Egr2	 in	these	mice	
had	 not	 been	 inherited,	 so	 they	 were	 wild	 type.	 However,	 heterogeneity	 was	 shown	
with	 the	 presence	 of	 both	 upper	 and	 lower	 bands	 (Figure	 3.2).	 In	 addition,	 the	
expression	 of	 GFP	was	measured	 by	 FACS	 (Figure	 3.3).	 As	 confirmed	 previously,	 the	























































in	 the	 locus	 of	 a	 mouse	 leads	 to	 a	 comparable	 expression	 level	 for	 every	 transgene	
introduced,	 in	which	the	endogenous	murine	promoter	controls	its	 level	of	expression	
(Menalled,	2005).		
In	 this	 study,	 the	 knock-in	 mice	 model	 was	 established	 using	 replacement	 of	 Egr2	
tagged	with	a	GFP	reporter	gene	using	homologous	recombination.	The	mice	model	was	





a	 high	 level	 of	 IL-2	with	decreased	 level	 of	 IFNγ	 and	 low	 level	 of	 IL-2	with	high	 IFNγ	
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expression	was	observed	in	our	transgenic	and	knockout	models	respectively	(Li	et	al.,	
2012).	 Our	 recent	 study	 showed	 a	 similar	 expression	 profile	 of	 GFP-Egr2+	 and	 GFP-













































The	nascent	 tumour	cells	 can	be	 identified	and	destroyed	by	 the	 immune	system	 in	a	
process	 called	 immunosurveillance	 that	 functions	 as	 the	main	 defence	 against	 cancer	
(Vesely	 et	 al.,	2011).	 T	 cell	 mediated	 immune	 response,	 including	 CD8	 and	 T	 helper	







are	 limited	 during	malignant	 progression	 by	 the	 development	 of	 immunosuppressive	
mechanisms	including	T	cell	deletion,	insufficient	T	cell	activation	and	peripheral	hypo-
responsiveness	 of	 anti-cancer	 T	 cells	 in	 the	 tumour	 microenvironment	 that	 drive	
immune	 evasion	 (Baitsch	 et	 al.,	2012).	 T	 cell	 hypo-responsiveness	 can	 be	 caused	 by	
clonal	 anergy	 or	 T	 cell	 exhaustion	 (Abe	 et	 al.,	 2012).	 Dendritic	 cells	 are	 central	
regulators	of	adaptive	immunity	and	their	maturation	is	vital	to	induce	co-stimulatory	
signals	 to	 T	 cells,	 but	 while	 dendritic	 cells	 maturation	 occurs	 in	 tumours	 and	
considering	suppressive	mechanisms	within	the	tumours,	inducing	potent	immunity	is	
insufficient	 (Gardner	 and	 Ruffell,	 2016).	 Several	 studies	 in	 metastatic	 melanoma	
patients	 have	 demonstrated	 that	 CD8+	T	 cells	 can	 be	 directed	 to	 melanocyte	
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differentiation	 antigens	 or	 tumour-restricted	 antigens,	 including	 MAGE-3,	 NY-ESO-1	
and	Melan-A/Mart-1,	 but	 they	 are	 not	 terminally	 differentiated	 (Roberta	 et	al.,	2003,	
Peterson	et	al.,	2003).	This	partial	maturation	of	anti-tumour	CD8+	T	cells	can	happen	




anti-tumour	 immunity	 (Harlin	 et	 al.,	2009).	 Chemokines,	 including	 CXCR4	 and	 CCR5,	




(Anderson	 et	al.,	2006,	 Best	 et	al.,	2013).	 Egr2	 is	 an	 essential	 regulator	 for	 the	 T	 cell	
immune	 response	 against	 viral	 infection	 by	 promoting	 T	 cell	 differentiation	 through	
binding	 to	Tbx21	and	 fostering	 the	expression	of	T-bet	 (Du	et	al.,	2014).	Moreover,	 in	
our	study,	Egr2	and	3	have	been	demonstrated	as	essential	regulators	for	the	efficient	
proliferation	 of	 naïve	 B	 and	 T	 cells	 in	 response	 to	 mitogenic	 antigen	 receptor	
stimulation,	 in	 which	 severe	 defects	 in	 B	 and	 T	 cell	 activation	 was	 evidenced	 by	
impaired	proliferation	and	production	of	IL-2	in	Egr2	and	Egr3	deficient	mice	model	(Li	





of	 Egr2	 in	 T	 cells	 and	 showed	 that	melanoma	 tumour	 growth	 is	markedly	 slowed	 in	
Egr2-deleted	 mice,	 indicating	 that	 cell-intrinsic	 expression	 of	 Egr2	 can	 contribute	 to	
tumour	 escape	 from	 immune	 destruction	 in	 vivo.	 To	 further	 examine	 the	 function	 of	
Egr2	in	tumour	growth	and	its	role	in	efficient	anti-tumour	therapy,	the	Egr2/3	KO	and	
WT	mice	models	were	used	in	our	study.	This	chapter	aimed	to	investigate	the	role	of	











was	 1	 mm.	 Mice	 were	 culled,	 and	 spleen	 and	 tumour	 tissues	 were	 harvested.	 After	





Figure	 4.1	 Tumour	 growth	 in	 Egr2/3	 KO	 and	 WT	 mice	 models.	 Tumours	 developed	 in	
subcutaneously	injected	B16	melanoma	mouse	14	days	after	inoculation.	Tumour	burden	ratio	was	










































































al.,	 2017).	 To	 assess	 Egr2	 expression	 in	 T	 cells	 under	 tumour	 conditions,	 CD8+	 TILs	
were	 isolated	 and	 analysed	 for	 Egr2	 expression.	 Results	 showed	 that	 10%	WT	 CD8+	
TILs	 expressed	 Egr2,	 while	 in	 CD8+	 cells	 from	 splenocytes,	 only	 5%	 expressed	 Egr2	































and	 CD44.	 Egr2/3	 KO	 CD8+	TILs/	 splenocytes	 and	WT	 CD8+	TILs/	 splenocytes	 were	 obtained	 from	
subcutaneously	injected	B16	melanoma	mice	14	days	after	inoculation.	The	cells	were	isolated	and	












Figure	 4.4	 Expression	 of	 Egr2	 in	 Egr2/3	 KO	 and	 WT	 CD8	 TILs/splenocytes.	 Egr2/3	 KO	 CD8+	




Egr2/3	 are	 important	 for	 clonal	 expansion,	 but	 suppress	 inflammatory	 cytokine	
production	in	T	cells	(Miao	et	al.,	2017).	To	explore	the	mechanism	for	the	role	of	Egr2	
in	 tumour	 growth,	 effector	 cytokines	 and	 cytotoxic	 molecules	 including	 IFNγ	 and	
Granzyme	B	were	assessed.	Results	showed	that	Granzyme	B	expression	in	Egr2/3	KO	
CD8	TILs	was	not	 significantly	different	 to	 their	wild	 type	counterparts	and	 IFNγ	was	














































































4.3.4	 CD8	 TILs	 produce	 more	 IL-2	 and	 are	 more	 proliferative	 than	 their	
counterparts	from	Egr2/3	KO	mice	
	
To	 further	 investigate	 the	 mechanism	 for	 the	 function	 of	 Egr2/3	 in	 TIL	 T	 cells,	 the	































































































































Tolerance	 to	 tumour	 antigens	 is	 one	 of	 the	 mechanisms	 for	 poor	 tumour	 immune	
responses	(Rabinovich	et	al.,	2007).	However,	the	mechanisms	are	unknown.	Recently,	
it	 has	 been	 reported	 that	 tumour	 infiltrating	 CD8+	T	 cells	 become	 anergic,	 with	
increased	 expression	 of	 Egr2,	 which	 drives	 the	 expression	 of	 anergic	 molecules	 like	
lymphocyte	 activation	 gene-3	 (LAG-3)	 and	 cytotoxic	 and	 regulatory	 T	 cell	 molecule	
(CRTAM),	 which	 may	 play	 role	 in	 tumour	 escape	 from	 immune	 destruction	 in	 vivo	
(Zheng	et	al.,	2012).	In	this	study,	we	have	now	found	that	deficiency	of	Egr2/3	results	
in	poor	immune	response	against	B16	tumour	models.	
Egr2	 and	 Egr3	 control	 the	 expression	 of	 Myc,	 a	 key	 transcriptional	 factor	 for	 T	 cell	
proliferation,	 in	 both	CD4	 and	CD8	T	 cells	 in	 response	 to	 viral	 infection	 (Wang	et	al.,	
2011,	 Nie	 et	 al.,	 2012).	 Egr2	 and	 3	 deficient	 B	 and	 T	 cells	 have	 shown	 impaired	
proliferation	as	evidenced	by	defects	in	IL-2	production.	It	was	also	demonstrated	that	
Egr2	is	required	for	AP-1	activity	by	directly	blocking	the	function	of	Batf,	a	suppressor	
of	AP-1,	highlighting	 the	 indispensable	role	of	Egr2	as	a	positive	regulator	 for	antigen	
receptor	induced	proliferation	in	adaptive	immune	responses	(Li	et	al.,	2012).	Increased	





et	 al.,	 2015).	 Abiko	 et	 al.	 demonstrated	 that	 IFNγ	 accelerates	 tumour	 growth	 by	
inducing	 PD-L1	 in	 the	 tumour	 in	 a	 subcutaneous	 model.	 Also,	 absolute	 numbers	 of	
	 101	
infiltration	 of	 CD8+	TILs	 are	 reduced	 by	 the	 expression	 of	 PD-L1.	 This	 suggested	 that	




tumour	 responses	 are	 not	 reduced	 in	 CD8	 TILs	 from	 Egr2/3	 KO	mice.	 However,	 the	
major	difference	is	the	expansion	of	CD8	TILs,	that	are	significantly	defect	in	Egr2/3	KO	
mice.	Also,	CD44	expression	was	higher	in	Egr2	positive	CD8	WT	TILs,	reflecting	that	
these	 cells	might	 have	 an	 effector	 function.	 Thus,	 the	 induction	 of	 Egr2/3	 in	 TIL	 T	















































antigen-specific	 T	 cells.	 During	 T	 cell	 activation,	 co-stimulatory	molecules,	 CD80	 and	
CD86,	 on	 APC	 bind	 to	 CD28	 enhance	 T	 cell	 proliferation	 and	 activate	 Th1	 and	 Th2	
immune	responses.	However,	co-inhibitory	molecules	such	as	PD-1,	CTLA-4	and	Lag-3	
serve	as	checkpoint	regulators	 to	control	 the	activation	of	T	cells	(Chen,	2004).	These	
molecules	 are	 highly	 induced	 in	 T	 cells	 in	 the	 tumour	microenvironment	 and	 play	 a	
major	 role	 in	 immune	 tolerance	 towards	 tumour	 (Vinay	and	Kwon,	2012,	Hernandez-
Chacon	et	al.,	2011).		
The	 central	 role	 of	 CTLA4	 for	 keeping	 T	 cell	 activation	 in	 check	 was	 dramatically	
demonstrated	 by	 the	 lethal	 systemic	 immune	 hyperactivation	 phenotype	 of	Ctla4-
knockout	 mice	 (Tivol	 et	 al.,	 1995,	 Waterhouse	 et	 al.,	 1995).	 The	 increased	 PD1	
expression	on	CD8+	TILs	may	either	reflect	an	anergic	or	exhausted	state,	as	has	been	
suggested	 by	 decreased	 cytokine	 production	 by	 PD1+	compared	with	 PD1−	TILs	 from	
melanomas	 (Ahmadzadeh	 et	 al.,	 2009).	 Lag-3	 co-expression	 on	 T	 cells	 is	 sustained	
during	 a	 tumour	 and	 chronic	 viral	 infection,	 that	 frequently	 co-express	 additional	
inhibitory	 receptors	 such	as	PD-1,	TIGIT,	TIM3,	 leading	 to	a	T	 cell	dysfunctional	 state	
exemplified	by	lack	of	proliferation,	cytokine	expression	and	catalytic	activity	(Andrews	
et	 al.,	 2017).	 Dual	 Blockade	 of	 PD-1	 and	 Lag-3	 synergises	 to	 enhance	 CD8+	T	 cell	
	 104	
responses	 during	 chronic	 viral	 infection,	 suggesting	 targeting	 multiple	 co-inhibitory	
receptor	 pathways	 to	 adjust	 T	 cell	 immune	 responses	 against	 persisting	 antigens	
(Blackburn	et	al.,	2009).		
Egr2	 and	 Egr3	 are	 critical	 for	 maintaining	 immune	 homeostasis	 and	 their	 crucial	
function	 as	 a	 checkpoint,	 controlling	 the	 transition	 between	 clonal	 expansion	 and	
differentiation	 in	effector	T	cells	was	recently	demonstrated	(Miao	et	al.,	2017).	Some	
tumour	 infiltrating	 CD8+	T	 cells	 become	 anergic,	 with	 increased	 expression	 of	 Egr2	
driving	the	expression	of	anergic	markers	like	LAG-3	and	CRTAM,	which	can	contribute	
to	tumour	escape	from	immune	destruction	in	vivo	(Zheng	et	al.,	2012).	Egr2-driven	cell	
surface	proteins	Lag-3,	PD-1	and	4-1BB	can	 identify	 a	 subpopulation	of	dysfunctional	
tumour	 antigen-specific	 CD8+	TIL,	 as	 reflected	 by	 defective	 IL-2	 production,	
contributing	 to	 the	 immune	 suppressive	 tumour	 microenvironment	 (Williams	 et	 al.,	
2014,	 Williams	 et	 al.,	 2017).	 Therefore,	 the	 role	 of	 Egr2	 in	 the	 regulation	 of	 these	
immune	 checkpoint	 molecules	 was	 studied	 in	 the	 tumour	 microenvironment	 in	 this	
chapter.		
5.3	Expression	of	immune	checkpoint	molecules	
Studies	 have	 shown	 that	 Egr2	 plays	 a	 role	 in	 driving	 the	 expression	 of	 immune	
checkpoint	molecules	such	as	Lag-3	and	PD-1	(Zheng	et	al.,	2012,	Williams	et	al.,	2014).	
To	pinpoint	 the	role	of	Egr2	 in	regulating	 immune	checkpoint	markers	under	 indirect	
and	 direct	 tumour	 conditions,	 CD8+	 splenocytes	 and	 CD8+	 TILs	 were	 isolated	 and	
















Also,	 Egr2/3	KO	CD8+	TILs	were	 not	 significantly	 different	 to	 GFP-Egr2	 CD8+	TILs	 in	
terms	of	expression	of	immune	checkpoint	markers	(Figure	5.1	&	5.2).	Collectively,	the	

























































of	 immune	 checkpoint	 molecules.	 Egr2/3	 KO	 CD8+	 splenocytes/TILs	 and	 GFP-Egr2	 CD8+	
splenocytes/TILs	 were	 obtained	 from	 subcutaneously	 injected	 B16	melanoma	mice	 14	 days	 after	










Figure	 5.2	 Expression	 of	 immune	 checkpoint	 molecules	 in	 Egr2/3	 KO	 and	 GFP-Egr2	 CD8	






























Immune	 checkpoint	 molecules	 play	 the	 non-redundant	 role	 in	 modulating	 immune	
responses,	providing	a	prognostic	role	and	promising	therapeutic	approaches	in	cancer	
and	autoimmunity	conditions	(Kyi	and	Postow,	2014,	Pardoll,	2012).	PD-1,	CTLA-4,	Lag-
3	are	 the	most	 successful	 targets	 for	 anti-tumour	 immune	 therapy	 (Flemming,	2012).	
These	 molecules	 are	 mostly	 induced	 in	 the	 tumour	 microenvironment	 (Seidel	 et	 al.,	
2018).	 Dual	 targeting	 of	 PD-1	 and	 Lag-3	 synergistically	 enhances	 the	 anti-tumour	
immune	 response	 in	 various	 tumour	 models	 by	 increasing	 CD4+	 and	 CD8+	 T	 cell	
infiltration	as	well	as	increased	IFNγ	and	TNFα	production	(Andrews	et	al.,	2017).	
We	established	 that	CD8+	TILs	 from	wild	 type	mice	have	similar	or	 low	expression	of	
these	 molecules,	 indicating	 Egr2/3	 function	 in	 TIL	 T	 cells	 is	 not	 due	 to	 counter-























anti-tumour	 responses.	 However,	 Egr2	 is	 a	 de	 novo	 transcription	 factor	 that	 is	 only	
expressed	 in	 pre-activated	 T	 cells	 by	 antigen	 stimulation	 (Zheng	 et	 al.,	 2012).	





Previously,	 our	 group	 showed	 that	 Egr2	 and	Egr3	 are	 rapidly	 induced	 by	 antigens	 in	
naïve	 T	 cells	 and	 promptly	 suppressed	 by	 IFNγ	 via	 inhibitory	 feedback	mechanisms,	
allowing	 optimal	 clonal	 expansion	 and	 coupling	 of	 expansion	 with	 effector	
differentiation	of	viral	responding	T	cells	(Miao	et	al.,	2017).	However,	the	regulation	of	
Egr2	 through	 IFNγ	 and	 Jak-STAT	 signalling	 pathway	 was	 not	 elucidated,	 so	 it	 was	
hypothesised	 that	 Egr2	 expression	 is	mediated	 through	 IFNγ/STAT1	 and	 IL-6/STAT3	
signalling	pathway.	
6.3	Egr2	expression	is	regulated	by	IL-2,	IL-4	and	IL-10	cytokines	
The	 cytokines	 are	 associated	 with	 T	 cell	 activation	 and	 produced	 in	 the	 tumour	
microenvironment	 are	 IL-2,	 IL-4,	 IL-6,	 IL-10,	 IL-12,	 INFγ	 and	TGF-β	 (Landskron	et	al.,	
2014).	Among	them,	IL-2,	IL-4	and	IL-10	share	an	important	promising	function	in	TILs,	







including	 IL-2,	 IL-4	 and	 IL-10	 increased	 Egr2	 induction	 and	 regulated	 its	 expression.	












































































10	 after	 24	 hours	 analysed	 for	 the	 induction	 of	 Egr2	 expression.	 A)	 Splenic	 CD8+	 T	 cells	 were	
isolated	and	cultured	in	vitro	with	anti-CD3	(2.5	µg/ml)	and	anti-CD28	(1.25	µg/ml)	in	the	presence	
of	 IL-2	and	 IFNγ	 (100	ng/ml)	 for	24	hours	and	analysed	by	 flow	cytometry.	B)	 Splenic	CD4+	T	 cells	
















cells	 by	 45%	 and	 60.06%,	 this	 expression	 was	 suppressed	 to	 10%	 and	 17.76	 in	 the	
presence	 of	 INFγ	 and	 IL-6	 respectively	 (Figure	 6.3	 A	 &	 B).	 As	 shown	 in	 Figure	 6.4,	























anti-CD28	 treated	cells	 (Figure	6.5).	These	results	demonstrate	 that	 INFγ	 and	 IL6,	 the	
major	 inflammatory	 cytokines	 in	 tumour	microenvironment,	 are	 repressors	 for	 Egr2	
expression	in	T	cells.	Our	results	may	indicate	the	suppression	of	Egr2	expression	in	T	


































































Figure	6.3	Dot	plots	of	 cultured	GFP-Egr2	CD4+	T	 cells	 in	 the	presence	of	 IFNγ 	 and	 IL-6	 after	 48	
hours	 analysed	 for	 the	 induction	 of	 Egr2	 expression.	 A)	 Splenic	 CD4+	T	 cells	 were	 isolated	 and	
cultured	 in	 vitro	 with	 anti-CD3	 (2.5	 µg/ml)	 and	 anti-CD28	 (1.25	 µg/ml)	 in	 the	 presence	 of	 IFNγ	
(200ng/ml)	 for	48	hours	and	analysed	by	flow	cytometry.	B)	Splenic	CD4+	T	cells	were	 isolated	and	














































To	 investigate	 the	 potential	 binding	 sites	 of	 STAT1	 and	 STAT3	 in	 the	 Egr2	 promoter	
region,	 we	 analysed	 3	 kb	 upstream	 of	 Egr2	 locus	 by	 functional	 regulatory	 elements	
multiple-sequence	 alignment	 analysis	 (Ovcharenko	 et	 al.,	 2005).	 There	 were	 four	
binding	 sites	 for	 STAT1	 and	 three	 sites	 for	 STAT3:	 5’-	 cGGAAgtg-3’,	 5’-
tttaatTTTCCGGAAtggctc-3’,	5’-cGGAAttc-3’	for	STAT1	and	5’-tttaatTTTCCGGAAtggctc-3’-	
and	 5’-cGGAAttc-3’	 for	 STAT3	 (Timofeeva	 et	 al.,	 2013).	 The	 STAT1	 binding	 sites	
partially	overlapped	with	STAT3,	cGGAAttc	and	tttaatTTTCCGGAAtggctc,	suggesting	that	
















inhibits	 the	 cytokine-induced	 activation	 of	 STAT1	 and	 STAT1-dependent	 gene	
transcription	 by	 substantially	 decreasing	 phosphorylation	 of	 STA1	 at	 Tyr701,	





GFP-Egr2	 CD4+	 T	 cells were	 stimulated	 with	 anti-CD3	 (2.5	 µg/ml)	 anti-CD28	 (1.25	
µg/ml)	in	the	presence	of	INFγ	(200ng/ml)	and	STAT1	inhibitor	(10µM),	increased	Egr2	
expression	 to	66.48%	 (Figure	6.7	A).	The	 induced	Egr2	 expression	 in	 the	presence	of	




the	 presence	 of	 IL-6	 and	 STAT3	 inhibitor	was	 highly	 significant	 (P=0.001)	 compared	
with	 anti-CD3/anti-CD28	 and	 IL-6	 treated	 samples	 (Figure	 6.9).	Moreover,	 the	 cells	
stimulated	only	with	the	Fludarabine	and	Stattic	did	not	express	Er2.		






















































































of	 IFNγ	 (200	ng/ml)	 for	 24	hours.	 The	 following	day,	 Fludarabine	 (10	µM)	was	 added	 to	 the	 cells,	
incubated	 for	 24	hours	 and	analysed	by	 flow	 cytometry.	 B)	 Splenic	 CD4+	T	 cells	were	 isolated	 and	
cultured	 in	 vitro	 with	 anti-CD3	 (2.5	 µg/ml)	 and	 anti-CD28	 (1.25	 µg/ml)	 in	 the	 presence	 of	 IL-6	
(200ng/ml)	for	24	hours.	The	following	day,	Stattic	(20	µM)	was	added	to	the	cells,	incubated	for	24	







































































Egr2	 expression,	 it	 still	 poses	 the	 question	 as	 to	whether	 this	mediatory	 role	 can	 be	
directly	related	to	Egr2	promoter	activity.	To	test	if	STAT1	is	involved	in	IFNγ	mediated	
Egr2	 expression,	 a	 luciferase	 reporter	 assay	 was	 performed	 with	 an	 Egr2-pGL2-b	
reporter	gene	containing	the	Egr2	promoter.	Analogous	to	previous	experiments,	IFNγ	



















vector	 (Egr2-pGL2-b)	 was	 transfected	 into	 EL4	 cells,	 then	 24	 hours	 after	 transfection,	 cells	 were	
treated	 with	 soluble	 anti-CD3	 (2.5	 µg/ml)	 in	 the	 presence	 and	 absence	 of	 IFNγ	 (200	 ng/ml)	 and	
fludarabine	 (10	 µM)	 for	 16–18	 hours.	 Cells	 were	 harvested	 for	 protein	 extraction	 followed	 by	





Several	 studies	 have	 highlighted	 the	 essential	 role	 of	 cytokines	 in	 inhibition	 and	
progression	of	tumours,	but	regulatory	mechanisms	in	TIL	proliferation	and	function	in	
immunosuppressive	 tumours	 are	 not	well	 understood	 (Zhou	 et	al.,	2014).	 Egr2-/-	 and	
Egr3-/-	 mice	 have	 demonstrated	 that	 Egr2	 and	 Egr3	 are	 important	 for	 anti-tumour	
responses	 in	 B16	 tumour	 models.	 Their	 function	 is	 associated	 largely	 with	 the	
expansion	of	TIL	T	cells,	but	less	with	the	function	of	TIL	T	cells.		
We	have	now	 investigated	 the	effects	of	cytokines	 that	have	been	reported	 in	 tumour	
microenvironment	 on	 the	 regulation	 of	 Egr2	 expression	 in	 T	 cells.	 The	 results	
demonstrated	that	the	cytokines,	IL-2	and	IL-4,	that	promote	T	cell	expansion	increased	
expression	 of	 Egr2	 in	 activated	 T	 cells,	 while	 pro-inflammatory	 cytokines,	 including	
IFNγ	 and	 IL-6,	 suppress	 Egr2	 expression.	 As	 TIL	 T	 cells	 from	 wild	 type	 mice	 are	
expanded	 significantly	 in	 comparison	 to	 TILs	 from	 Egr2/3	 KO	mice,	 the	mechanisms	
reported	from	TIL	T	cells	after	IL-2	and	IL-4	treatment	may	result	partly	from	induction	
of	 Egr2	 (Rosenberg,	 2014).	However,	 the	 pro-inflammatory	 cytokines	 have	 effects	 on	
both	the	function	of	TIL	T	cells	and	tumour	metastasis	(Landskron	et	al.,	2014).	These	
cytokines	have	been	reported	to	have	a	negative	impact	on	TIL	expansion	(Abiko	et	al.,	
2015),	 therefore,	 excessive	 production	 of	 these	 cytokines	 by	 the	 tumour	





















responses	 and	 they	 play	 crucial	 role	 in	 controlling	 the	 inflammation	 and	 antigen-
induced	proliferation	of	B	and	T	cells	(Li	et	al.,	2012).	A	recent	study	demonstrated	that	
Egr2	and	Egr3	are	rapidly	induced	by	the	antigens	in	naïve	T	cells,	which	are	required	
for	 clonal	 expansion	 of	 antigen-specific	 T	 cells.	 Also,	 the	 expression	 of	 Egr2/3	 is	
suppressed	 by	 inflammatory	 cytokines,	 such	 as	 IFNγ,	 through	 inhibitory	 feedback	
mechanisms.	 This	 mechanism	 allows	 optimal	 clonal	 expansion	 and	 coupling	 of	
expansion	 with	 effector	 differentiation	 of	 responding	 T	 cells	 against	 viral	 infection,	
which	proves	their	 indispensable	role	 in	 limiting	 immunopathology	during	productive	
adaptive	 immune	 responses	 (Miao	 et	 al.,	 2017).	 Egr2,	 through	 promoting	 T	 cell	
differentiation	and	 fostering	 the	expression	of	T-bet,	 is	 a	 vital	 regulator	 for	 the	T	 cell	
immune	response	against	viral	infection	(Du	et	al.,	2014).	
The	 findings	 from	 this	 study	 showed	 that	 Egr2/3	 are	 important	 for	 T	 cell	 mediated	
immune	 responses	 in	 tumours	 by	 promoting	 the	 expansion	 of	 tumour	 infiltrating	 T	
cells.	 In	 the	 absence	 of	 Egr2/3,	 tumour	 infiltrating	T	 cells	were	 significantly	 reduced,	
with	 a	 low	 expression	 of	 Ki-67,	 a	 proliferating	 marker	 and	 IL-2.	 These	 results	 were	
associated	with	over	growth	of	B16	melanoma	tumours.	However,	the	effector	function,	
such	as	production	of	 IFNγ	and	Granzyme	B,	was	not	affected	or	 increased	 in	Egr2/3	
deficient	T	cells,	indicating	the	importance	of	the	expansion	of	tumour	specific	T	cells	in	
anti-tumour	responses.	Moreover,	Egr2	expression	 is	regulated	by	different	cytokines,	
including	 IL-2	 and	 IL-4	 that	 increased	 Egr2	 induction	 in	 activated	 T	 cells.	 However,	






from	 Egr2/3	 deficient	 T	 cells	 from	 TILs	 that	 Egr2/3	 are	 not	 directly	 involved	 in	 the	
regulation	of	immune	checkpoint	molecules	in	the	tumour	microenvironment.	
7.2	 Egr2/3	 are	 important	 for	 efficient	 T	 cell	 immune	 responses	
against	tumours	
Immune	 therapies	with	anti-checkpoint	 regulators,	 such	as	anti-PD-1	and	anti-CTLA4,	
have	 outstanding	 efficacy	 for	 multiple	 solid	 tumours	 (Seidel	 et	 al.,	 2018),	 which	
demonstrate	 that	 tumour	 specific	 immune	 responses	 of	 T	 cells	 are	 important	 for	
controlling	 tumours	and	the	 tumour	microenvironment	 induces	checkpoint	regulators	
to	escape	 immune	surveillance	(Pardoll,	2012).	However,	 it	 is	not	known	whether	the	
tumour	specific	T	cells	are	suppressed	for	their	proliferation	or	effector	function	or	both	
(Chen	and	Mellman,	2013).	Consistent	observations	demonstrated	that	the	number	of	T	
cells	 in	 TILs	 is	 associated	 with	 the	 survival	 rate	 of	 cancer	 patients	 in	 multiple	 solid	
tumours	 (Abiko	 et	 al.,	 2015),	 indicating	 the	 expansion	 of	 TIL	 T	 cells	 may	 be	
fundamentally	 important,	 while	 inflammatory	 effectors	 without	 proliferation	 will	
negatively	impact	on	anti-tumour	activity.	Lack	of	both	TIL	proliferation	and	sensitivity	





mitogenic	 antigen	 receptor	 stimulation.	 Egr2	 also	 plays	 an	 essential	 role	 in	 the	
	 131	
regulation	of	the	transition	between	the	clonal	expansion	and	differentiation	of	effector	
T	 cells	 during	 infection	 (Li	 et	al.,	 2012,	Miao	 et	al.,	2017).	 In	 this	 study,	 considerably	
high	 tumour	growth	was	observed	 in	Egr2/3	KO	mice	model	 in	 comparison	with	WT	
mice.	 Moreover,	 CD8+	 TIL	 expansion	 was	 significantly	 defected	 in	 Egr2/3	 KO	 mice,	
however,	effector	cytokine	induction	was	not	impaired.	This	provided	a	mechanism	by	
which	Egr2/3	can	promote	TIL	expansion,	resulting	in	tumour	regression.	Collectively,	
it	 was	 demonstrated	 that	 Egr2/3,	 a	 component	 of	 the	 tumour	 microenvironment,	
efficiently	 promotes	 anti-tumour	 CD8+	 T	 cell-mediated	 immune	 response	 in	 vivo,	
significantly	contributing	to	tumour	regression.	
7.3	Role	of	Egr2	and	Egr3	 in	 the	 regulation	of	 Immune	checkpoint	
molecules	
Immune	checkpoints	are	incorporated	into	the	immune	system	that	play	an	important	
role	 in	 maintaining	 self-tolerance	 and	 modulating	 the	 amplitude	 and	 duration	 of	
immune	 responses	 against	 infection	 and	 cancer	 (Pardoll,	 2012).	 The	 cell	 surface	
proteins	 Lag-3,	 PD-1	 and	 4-1BB	 induced	 by	 Egr2	 can	 identify	 a	 subpopulation	 of	
dysfunctional	tumour	antigen-specific	CD8+	TIL,	as	shown	by	defective	IL-2	production,	
leading	 to	 immune	 suppressive	 tumour	 microenvironment	 (Williams	 et	 al.,	 2014,	
Williams	et	al.,	2017)	(Table	7.1).	PD-1	and	Lag-3	targeting	through	increased	CD4+	and	
CD8+	T	 results	 in	 a	 coordinated	 immune	 activation	 in	 the	 large-tumour	 setting	 and	 a	
significantly	 higher	 survival	 rate	 (Andrews	 et	 al.,	 2017).	 This	 emphasises	 the	





in	 Egr2/3	 KO	 mice	 in	 comparison	 with	 GFP-Egr2	 mice.	 Previously,	 our	 group	
demonstrated	that	the	loss	of	self-tolerance	and	development	of	lupus-like	autoimmune	
disease	 in	 Egr2/3	 KO	mice	 (Zhu	 et	 al.,	 2008).	 In	 line	 with	 our	model,	 this	 enhanced	
expression	of	 immune	 checkpoint	molecules	 could	be	 related	 to	 the	 tangible	 effect	 of	
inflammation	that	could	be	exerted	on	the	expression	of	immune	checkpoint	molecules.	





The	 pivotal	 role	 of	 the	 cytokines	 in	 the	 progression	 and	 suppression	 of	 tumours	 has	
been	studied	in	several	studies	(Zhou	et	al.,	2014).	It	has	been	shown	that	IL-2,	IL-4	and	
IFNγ	 play	 fundamental	 roles	 in	 TIL	 T	 cells	 and	 cancer	 immunotherapy	 (Jiang	 et	 al.,	
2016).	 IL-2	 and	 IL-4	 encourage	T	 cell	 proliferation	 and	 infusion	of	 these	 cytokines	 in	




T	 cell	 clonal	 expansion	 and	 a	 negative	 feedback	 mechanism	 exerted	 by	 effector	
cytokines,	such	as	 IFNγ,	 is	 important	 to	boost	T	cell	differentiation	(Miao	et	al.,	2017).	
With	 these	 key	 findings	 in	 mind,	 we	 set	 out	 to	 establish	 the	 mechanism	 by	 which	






T	cell	expansion	 in	activated	T	cells,	while	excessive	production	of	 IFNγ	 and	 IL-6	may	
inhibit	T	cell	expansion	 through	 the	suppression	of	Egr2	 in	activated	T	cells,	with	 the	
latter	 providing	 a	 distinct	 mechanism	 for	 tolergenic	 effects	 of	 the	 tumour	


















NFAT4-/-			T	cells	 Positive	 Rengarajan	 et	 al.,	 2000;	






























cells	 has	 been	 demonstrated.	 Based	 on	 the	 findings	 reported,	 we	 investigated	 the	
function	 of	 Egr2	 in	 adaptive	 immunity	 using	 a	 B16	 melanoma	 tumour	 model.	 The	
results	 showed	 that	 significant	 Egr2	 expression	 in	 T	 cells	 under	 tumour	
microenvironment	 can	 result	 in	 enhanced	 CD8+	 TIL	 expansion,	 whereas	 Egr2/3	 KO	
counterparts	showed	higher	tumour	growth	followed	by	impaired	CD8+	TIL	expansion.	





Egr2	 expression	 in	 activated	 T	 cells,	 suggesting	 a	 distinct	 tolerant	mechanism	 of	 the	
tumour	 microenvironment	 to	 the	 immune	 response.	 Moreover,	 Egr2	 expression	 was	
mediated	through	IFNγ/STAT1	and	IL-6/STAT3	signalling	pathways	(Figure	7.1).	Lastly,	








signalling	 pathways	 in	 the	 adaptive	 immune	 response.	 Upon	 antigen	 (positive	 for	 Egr2	
expression)	 and	 cytokine	 stimulation	 (including	 INFγ	 and	 IL-6	 and	 negative	 for	 Egr2	
expression),	 STAT1	 inhibitor	 (Fludarabine)	 and	 STAT3	 inhibitor	 (Stattic)	 block	 tyrosine	












potential	 effector	mechanisms	within	 this	mice	model	 for	 developing	 a	 strong	 strategy	
against	cancers.	For	the	regulation	of	Egr2	through	the	cytokine	STAT	(IFN-γ/STAT1	and	
IL-6/STAT3)	 signalling	 pathway,	 it	 would	 be	 interesting	 to	 quantify	 the	 expression	 of	
Egr2	and	Egr3	during	T	cell	signalling	and	investigate	the	mechanisms	of	other	cytokines;	
as	we	have	found	an	enhancing	effect	of	IL-2,	IL-4	and	IL-10	in	terms	of	Egr2	expression.	
This	will	help	 to	 find	out	mechanisms	 in	boosting	T	cell	proliferation	and	 functions	 for	
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